Page last updated: 2024-08-24

glucose, (beta-d)-isomer and Cardiovascular Diseases

glucose, (beta-d)-isomer has been researched along with Cardiovascular Diseases in 313 studies

Research

Studies (313)

TimeframeStudies, this research(%)All Research%
pre-19902 (0.64)18.7374
1990's1 (0.32)18.2507
2000's2 (0.64)29.6817
2010's206 (65.81)24.3611
2020's102 (32.59)2.80

Authors

AuthorsStudies
Johnston, TP; Korolenko, TA; Pirro, M; Sahebkar, A1
Caputi, AP; Cuzzocrea, S; Falciani, M; Filippelli, A; Rossi, F; Zingarelli, B1
Brueckmann, M; Butler, J; Fitchett, DH; George, JT; Inzucchi, SE; Mattheus, M; Ofstad, AP; Sattar, N; Vaduganathan, M; Verma, S; Wanner, C; Zinman, B1
Ferreira, JP; Inzucchi, SE; Mattheus, M; Meinicke, T; Steubl, D; Wanner, C; Zinman, B1
Bessette, LG; Brodovicz, KG; Déruaz-Luyet, A; Glynn, RJ; Najafzadeh, M; Paik, JM; Patorno, E; Pawar, A; Schneeweiss, S; Wexler, DJ1
Brand, SB; Kansal, AR; Koitka-Weber, A; Kuti, E; Pfarr, E; Reifsnider, OS; Stargardter, M; Ustyugova, A; Wang, C; Wanner, C1
Egocheaga, I; Escobar, C; Obaya, JC; Pallarés, V1
Anker, SD; Kaku, K; Lund, SS; Mattheus, M; Pocock, S; Wanner, C; Yasui, A1
Bhatt, DL; Gause-Nilsson, I; Kolkailah, AA; Leiter, LA; McGuire, DK; Mosenzon, O; Murphy, SA; Raz, I; Sabatine, MS; Wilding, JPH; Wiviott, SD1
Chaitoff, A; Fischer, MA; Gong, J; Niforatos, JD1
Brandt, NH; Ersbøll, M; Faber, J; Gustafsson, F; Gæde, PH; Hasbak, P; Inzucchi, SE; Jürgens, M; Kistorp, CM; Kjær, A; Rossing, P; Schou, M; Wolsk, E; Zerahn, B1
Bové, KB; Nilsson, M; Prescott, E; Suhrs, HE; Zander, M1
Inzucchi, SE; Kahl, S; Ofstad, AP; Roden, M; Sattar, N; Schüler, E; Wanner, C; Zinman, B1
Aboalhasan, E; Arbel, R; Azuri, J; Hammerman, A; Moore, CM1
García, Á; Gil-Rojas, Y; Lasalvia, P1
Balasubramanian, P; Elsaesser, A; Ferreira, JP; Inzucchi, SE; Ofstad, AP; Wanner, C; Zinman, B1
Anker, SD; Fitchett, DH; Inzucchi, SE; Lauer, S; Pernille Ofstad, A; Sander, LE; Vedin, O; Verma, S; Wanner, C; Yaggi, HK; Zinman, B1
Chen, Y; Deng, X; Fang, Y; Kan, Q; Liu, Y; Man, H; Shang, J; Shi, X; Tang, S; Wang, D; Wang, L; Wang, P; Wei, W; Yang, H; Yang, J; Yuan, H; Yuan, Q; Zhang, C; Zhang, Y1
Cherney, DZI; Chertow, GM; Correa-Rotter, R; Heerspink, HJL; Jongs, N; Langkilde, AM; Mann, JFE; McMurray, JJV; Mosenzon, O; Rossing, P; Stefansson, BV; Toto, RD; Vart, P; Waijer, SW; Wheeler, DC1
Shao, G1
Dural, İE; Ersoy, İ; Sarı, A1
Hansmann, J; Lizio, R; Ockermann, P1
Huang, K; Liu, J; Sun, S; Wang, Y; Xie, X; Zhou, W; Zhu, D; Zhu, Q1
Barreto, J; Bonilha, I; Breder, I; Breder, J; Coelho, OR; Coelho-Filho, OR; de Carvalho, LSF; do Carmo, HR; Kimura-Medorima, ST; Lima, M; Luchiari, B; Matos-Souza, JR; Moura, FA; Munhoz, D; Nadruz, W; Oliveira, A; Oliveira, D; Quinaglia, T; Sposito, AC; Wolf, V1
Dixen, U; Fenger, M; Goetze, JP; Holst, JJ; Jørgensen, NB; Madsbad, S; Madsen, PL; Richter, EA; Thirumathyam, R; Van Hall, G; Vejlstrup, N1
Slomski, A2
Abdelmalak, NS; Hammad, RW; Latif, R; Sanad, RA1
Doumas, M; Karagiannis, A; Katsimardou, A; Papadopoulos, C; Patoulias, D; Zografou, I1
Aleksandric, M; Fülöp, T; Gumprecht, J; Kamenov, Z; Medvedchikov, A; Prázný, M; Rosenzweig, D; Suplotova, L1
Cho, GY; Choi, HM; Hwang, IC; Lim, J; Yoon, YE1
Ageev, FT; Ametov, AS; Antsiferov, MB; Arutyunov, GP; Cherkashin, DV; Fomin, IV; Galstyan, GR; Galyavich, AS; Gilyarevskiy, SR; Glezer, MG; Ilyin, MV; Khalimov, IS; Khasanov, NR; Lebedeva, AI; Lopatin, YM; Nedogoda, SM; Salukhov, VV; Tarlovskaya, EI; Tereshchenko, SN; Villevalde, SV; Vinogradova, NG; Yakushin, SS; Zhirov, IV1
Catharina de Beer, J; Ker, J; Miller-Janson, H; Snyman, J; Stander, M1
Advani, A; Cherney, DZI; Dubrofsky, L; Kugathasan, L1
Bég, SA; Dar, MS; Kaspers, S; Marx, N; Mattheus, M; Ofstad, AP; Wanner, C1
Cauchon, M; Lanthier, L; Plourde, ME; Viau-Trudel, A1
Ding, Y; Liu, Y; Peng, Y; Wang, H; Wang, Y; Zhang, X; Zhang, Y1
Candido, R; Cucinotta, D; Graziano, G; Manicardi, V; Nicolucci, A; Rocca, A; Rossi, MC; Tuccinardi, F1
Avogaro, A; Bonora, BM; Fadini, GP; Vigili de Kreutzenberg, S1
Handelsman, Y2
Gippini, A; Prado, A1
Abraitienė, A; Ametov, AS; Gaàl, Z; Gumprecht, J; Janež, A; Karasik, A; Kaser, S; Lalić, K; Mankovsky, BN; Moshkovich, E; Past, M; Prázný, M; Radulian, G; Schernthaner, G; Smirčić Duvnjak, L; Tkáč, I; Trušinskis, K1
Al-Omran, M; Bhatt, DL; Connelly, KA; Dhingra, N; Hess, DA; Leiter, LA; Mason, T; Mazer, CD; Quan, A; Rotstein, OD; Sabongui, S; Teoh, H; Terenzi, DC; Trac, JZ; Verma, S; Yan, AT; Zinman, B1
Fitchett, D; George, JT; Inzucchi, SE; Johansen, OE; Mattheus, M; Vedin, O; Wanner, C; Zinman, B1
Anand, IS; Bělohlávek, J; Bengtsson, O; Böhm, M; Chiang, CE; Chopra, VK; de Boer, RA; DeMets, DL; Desai, AS; Diez, M; Docherty, KF; Drozdz, J; Dukát, A; Ge, J; Held, C; Howlett, JG; Inzucchi, SE; Jhund, PS; Katova, T; Kitakaze, M; Kosiborod, MN; Køber, L; Langkilde, AM; Ljungman, CEA; Martinez, FA; McMurray, JJV; Merkely, B; Nicolau, JC; O'Meara, E; Petrie, MC; Ponikowski, P; Sabatine, MS; Schou, M; Sjöstrand, M; Solomon, SD; Tereshchenko, S; Verma, S; Vinh, PN1
Chan, YY; Chang, KC; Chen, HY; Hung, MJ; Kao Yang, YH; Lai, EC; Shao, SC; Yang, NI1
Bergenstal, RM; Fitchett, D; George, JT; Hantel, S; Inzucchi, SE; Kaspers, S; Kiš, SG; Monteiro, P; Toural, E; Zinman, B1
Moist, L2
Cahn, A; Cernea, S; Raz, I1
Brandt, NH; Faber, J; Gustafsson, F; Gæde, PH; Hasbak, P; Inzucchi, S; Jürgens, M; Kistorp, CM; Kjær, A; Rossing, P; Schou, M; Wiberg, M; Wolsk, E; Zerahn, B1
Fitchett, D; George, JT; Hantel, S; Inzucchi, SE; Janista, C; Jurišić-Eržen, D; Kaspers, S; Woo, V; Zinman, B1
Canivell, S; Franch-Nadal, J; Gratacòs, M; Mata-Cases, M; Mauricio, D; Real, J; Vlacho, B1
Aguiar, C; Birne, R; Branco, P; Calado, J; Matos, P; Melo, M; Monteiro, P; Polónia, J; Silva-Nunes, J1
Fuchigami, A; Higa, M; Hirose, T; Hiyoshi, T; Ichijo, T; Inoue, I; Iso, K; Kitazawa, T; Kumashiro, N; Okada, Y; Shigiyama, F; Yoshii, H1
Al-Bazz, DY; Wilding, JP1
Foresto, RD; Gonzalez, DE; Ribeiro, AB1
Masuda, D; Yamashita, S1
Chertow, GM; Correa-Rotter, R; Greene, T; Heerspink, HJL; Hou, FF; Langkilde, AM; Lindberg, M; McMurray, J; Rossing, P; Stefansson, BV; Toto, R; Wheeler, DC1
Chan, YY; Chang, KC; Hung, MJ; Kao Yang, YH; Lai, EC; Lin, YH; Shao, SC1
Broedl Md, UC; Coleman, RL; Fitchett, D; George, JT; Gray, AM; Holman, RR; Woerle, HJ; Zinman, B1
Anand, I; Belohlávek, J; Bengtsson, O; Böhm, M; Boulton, D; Chiang, CE; Chopra, VK; de Boer, RA; Desai, AS; Diez, M; Docherty, KF; Drozdz, J; Dukát, A; Ge, J; Greasley, PJ; Howlett, J; Inzucchi, SE; Jhund, PS; Johanson, P; Katova, T; Kitakaze, M; Kosiborod, MN; Køber, L; Langkilde, AM; Ljungman, CEA; Martinez, FA; McMurray, JJV; Merkely, B; Nicolau, JC; O'Meara, E; Petrie, MC; Ponikowski, P; Sabatine, MS; Schou, M; Sjöstrand, M; Solomon, SD; Tereshchenko, S; Verma, S; Vinh, PN1
Brueckmann, M; Butler, J; Fitchett, D; George, JT; Inzucchi, SE; Mazer, CD; Ofstad, AP; Sharma, A; Verma, S; Wanner, C; Zinman, B; Zwiener, I1
Ghosal, S; Sinha, B1
Fonseca, VA; Shao, H; Shi, L1
Eliasson, B; Franzén, S; Gudbjörnsdottir, S; Hveem, K; Jonasson, C; Melbye, M; Pasternak, B; Svanström, H; Svensson, AM; Ueda, P; Wintzell, V1
Anwar, MM; Awad, M; Carapinha, JL; Elebrashy, I; Elhadad, H; Elsisi, GH; Khattab, M; Wafa, A1
Ferreira, JP; Fitchett, D; George, JT; Kraus, BJ; Lauer, S; Ofstad, AP; Rossignol, P; Wanner, C; Zannad, F; Zinman, B; Zwiener, I1
Aboalhasan, E; Arbel, R; Azuri, J; Hammerman, A1
Fitchett, DH; George, JT; Inzucchi, SE; Khunti, K; Mattheus, M; Ofstad, AP; Wanner, C; Zinman, B1
Higashi, Y; Hisauchi, I; Machii, N; Matsuzawa, Y; Node, K; Okada, Y; Shima, KR; Shimabukuro, M; Taguchi, I; Takamura, T; Tanaka, A; Teragawa, H; Tomiyama, H; Toyoda, S; Ueda, S; Yamaoka-Tojo, M1
Bhatt, DL; Cahn, A; Fredriksson, M; Gause-Nilsson, IAM; Goodrich, EL; Kooy, A; Langkilde, AM; Leiter, LA; Litwak, L; McGuire, DK; Mosenzon, O; Murphy, SA; Raz, I; Rozenberg, A; Sabatine, MS; Wilding, JPH; Wiviott, SD; Yanuv, I1
Batiushin, M; Bilchenko, O; Cherney, DZI; Chertow, GM; Correa-Rotter, R; Douthat, W; Dwyer, JP; Escudero, E; Furuland, H; Górriz, JL; Greene, T; Haller, H; Heerspink, HJL; Hou, FF; Isidto, R; Kang, SW; Kashihara, N; Khullar, D; Langkilde, AM; Lindberg, M; Mark, PB; McMurray, JJV; Nowicki, M; Pecoits-Filho, R; Persson, F; Rossing, P; Sjöström, CD; Stefansson, BV; Toto, RD; Umanath, K; Van Bui, P; Wheeler, DC; Wittmann, I1
Aasen, T; Abdul Moin, NI; Abdul Wafi, S; Aboukameel, A; Abu-Bakar, N; Acharya, A; Ackermans, L; Adaramoye, O; Adarsh, KV; Adeosun, WA; Ahmad, NH; Ahmadi, F; Akanni, O; Akbar, M; Akbulak, RO; Akev, N; Akkaya, Ö; Al-Rashed, S; AlAbbad, S; Alabi, O; Alappat, BJ; Alcalá, S; Alcoutlabi, M; Aleppo, G; Alexander Ross, JB; Alexander, JH; Alexander, R; Alias, A; Alimba, C; Alken, FA; Allan, R; Alpers, M; Alsbou, EM; Amarasiri, SS; An, T; Anastasiadis, F; Anastassiadou, M; Anderson, KC; Andronikos, P; Anheyer, D; Annapurna, K; Anorlu, RI; Anten, MM; Anthopoulos, TD; Araujo-Castillo, RV; Aravamudhan, S; Arawwawala, LDAM; Arulsamy, N; Arunamata, A; Asghar, A; Asiri, AM; Aslanidou, T; Astrakhantseva, IV; Astutik, E; Attanayake, AP; Atwater, BD; Audureau, E; Augusto, S; Bakare, A; Banach, M; Bandelier, P; Banerjee, S; Barral, M; Bascuñán, J; Bates, FS; Bauer, NJC; Bayrak, BB; Beck, RW; Beckervordersantforth, J; Beeri, R; Begum, R; Beldi-Ferchiou, A; Bellingham, G; Ben-Tal, N; Bendib, I; Bergenstal, RM; Berger, MF; Bernasconi, G; Berry, S; Beuvon, F; Bi, WJ; Bi, Z; Bianconi, V; Bibi, I; Blank, BR; Bliemeister, E; Bobkowski, W; Bode, AM; Booth, CM; Bose, U; Boyd, K; Brancato, A; Brenmoehl, J; Brogi, E; Bronzo, P; Brooks, T; Brown, D; Brown, DN; Bruce, D; Buan, MEM; Bueno-Hernández, F; Bugielski, B; Bulavaitė, A; Buscagan, TM; Buxton, R; Caffaro, MM; Cai, Q; Cai, X; Cai, Y; Calhoun, P; Callander, N; Cambier, S; Camparo, P; Canales-Vargas, EJ; Canham, K; Cantu, J; Cao, J; Cao, JW; Cao, P; Cao, T; Cao, X; Caravella, BA; Carcadea, E; Carè, J; Carmichael, P; Carrasco Cabrera, L; Carteaux, G; Carvalho, PDS; Casarez, E; Cazorla, M; Celestrin, CP; Chakraborty, NK; Chan, B; Chandarlapaty, S; Chandgude, AL; Chang, CC; Chang, JH; Chang, X; Chang, Y; Chankhanittha, T; Chantanis, S; Chapovetsky, A; Chavan, S; Chen, B; Chen, D; Chen, F; Chen, G; Chen, H; Chen, J; Chen, K; Chen, KJ; Chen, KP; Chen, L; Chen, MA; Chen, Q; Chen, S; Chen, W; Chen, WF; Chen, X; Chen, Y; Cheng, D; Cheng, J; Cheng, Q; Cheon, GJ; Chiu, SC; Cho, CH; Cho, J; Choi, H; Choi, JS; Choi, YH; Christie, P; Chu, CH; Chu, Y; Chung, DH; Chung, F; Cline, JP; Cohen, A; Cohen, AD; Cohen, NJ; Comen, E; Compter, I; Cong, J; Cong, Z; Cooper, A; Cornud, F; Costa, C; Costa, S; Covey, A; Cowan, AM; Cramer, H; Cruz-Rivera, C; Cui, J; Cui, M; Cui, Y; Cui, YH; Culquichicón, C; Cushman, T; D'Auria, SJ; da Silva, J; Dalgediene, I; Danenberg, HD; Das, S; Dasgupta, K; Daubit, IM; de Oliveira, PD; de Prost, N; De Ruysscher, D; Dearman, K; Decato, D; Delfau-Larue, MH; Deng, L; Dhakate, SR; Dharuman, V; Di Costanzo, N; Dickler, MN; Dinehart, EE; Ding, D; Dinh, TK; Divya, KP; Djifack Tadongfack, T; Do, T; Domínguez-Roldan, R; Domínguez-Zambrano, E; Dömling, A; Donato, MD; Dong, JH; Dong, W; Dong, X; Dong, XR; Dong, Y; Dong, Z; Downs, M; Drutskaya, MS; Du, B; Du, F; Du, H; Du, L; Du, X; Duan, Z; Duangthip, D; Dunstand-Guzmán, E; Duong, F; Eckert, DJ; Edelhäuser, BAH; Eekers, DBP; Efendi, F; Efraimidis, P; Ehrenberg, H; Ehsanbakhsh, Z; Eickholt, C; Eksterowicz, J; El Mobadder, M; El-Araby, IE; El-Magd, MA; El-Tarabany, MS; Elgorban, AM; Engelmann, D; English, KL; Esfandiari, H; Eslami, B; Espinosa-Cuevas, A; Eswara, S; Faber, E; Fan, XH; Fan, Y; Fang, J; Fang, Z; Fantin, VR; Fei, P; Feng, G; Feng, H; Feng, J; Feng, X; Feng, XJ; Fennell, TR; Fernández-Moreira, V; Ferraz, ABF; Ferreras, KN; Flores, K; Flores-Pérez, I; Flox, C; Fluharty, FL; Fokouong Tchoffo, E; Folefack, GO; Foroutan, T; Fort, D; Fourati, S; Fousas, S; Frapard, T; Freguia, S; Friedman, DJ; Friedman, LS; Fu, D; Fu, Q; Fu, Y; Fujinami, S; Furihata, K; Gal, RL; Gan, H; Gao, C; Gao, F; Gao, R; Gao, SS; Gao, W; Gao, XC; Gao, Y; Gao, Z; Garozi, L; Ge, J; Georgiopoulos, A; Gerakiou, K; Ghazimirsaeed, SM; Ghazimirsaeed, ST; Gimeno, MC; Gjestad, R; Glurich, I; Goetchius, E; Goland, S; Goldstein, S; Gonçalves, CM; Gonçalves, H; Gong, Q; Gonzalez, D; Goplen, FK; Gorshkova, EN; Gotsman, I; Govindasamy, V; Granger, CB; Greco, L; Grigoriadou-Skouta, E; Grigoropoulos, P; Grivicich, I; Gromov, NV; Gruber, S; Grytczuk, M; Grzech-Leśniak, K; Gu, L; Gu, S; Gu, Z; Guadagnini, D; Guan, H; Guilliams, M; Guo, J; Guo, L; Gupta, A; Gupta, SK; Gurzu, S; Gutleb, AC; Haban, A; Hablitz, JJ; Hadisuyatmana, S; Hahn, S; Haiges, R; Hallal-Calleros, C; Hamed, M; Hammad, N; Hammer, N; Han, C; Hao, Y; Harnett, J; Has, EMM; Hassanpour, K; Hatzopoulos, D; Hawaldar, R; He, X; He, Y; He, YY; He, Z; Heberman, D; Heckl, D; Hegde, H; Henson, MA; Hernández-Velázquez, VM; Herrera, E; Hijazi, Z; Hirayama, K; Hirth, JM; Hoeben, A; Hohnloser, SH; Hong, M; Hood, K; Hoplock, LB; Hopman, WM; Horlbogen, LM; Hossein Rashidi, B; Hou, G; Hou, H; Hou, J; Hou, Y; Hu, J; Hu, W; Hu, X; Hua, W; Huang, G; Huang, H; Huang, J; Huang, T; Huang, W; Huang, Y; Huang, YD; Huang, Z; Hudis, CA; Hue, S; Huo, J; Hussain, M; Hvas, AM; Ichii, T; Ide Zeuna, J; Ilyas, S; Inoue, T; Iranzo, A; Irfan, M; Iwasa, Y; Iwashita, Y; Izgorodina, EI; J R, A; Jaber, WA; Jaborek, JR; Jacobus, SJ; Jadeja, SD; Jafarabadi, M; Jalan, D; Jamil, MI; Jarrah, S; Jarvis, D; Jayatilaka, KAPW; Jemal-Turki, A; Jeon, YK; Jeong, N; Jeong, SH; Jeong, SY; Jermy, M; Jhaveri, K; Ji, H; Ji, K; Ji, RY; Jiang, F; Jiang, J; Jiang, X; Jiang, Y; Jiao, Q; Jilani, K; Jiménez-Guerrero, P; Jin, L; Jo, YH; Johnson, JG; Johnson, ML; Jones, WS; Jose, S; Jularic, M; Jung, I; Jung, YJ; Jungen, C; Junttila, MR; Kache, S; Kahanovitch, U; Kalantzi, KI; Kallio, T; Kamnoedboon, P; Kang, CH; Kang, H; Kang, J; Kang, KW; Kapoor, P; Karmakar, D; Kartalis, A; Kauranen, P; Kazocina, A; Keikha, F; Keltai, M; Kershaw, SV; Kettani, M; Khalvati, S; Khandhar, S; Khosla, N; Kiely, CJ; Kim, CC; Kim, H; Kim, MJ; Kim, Y; Kim, YH; Kim, YT; Kimoto, E; Kiyu, A; Klatt, N; Kobayashi, M; Koh, J; Köhler, R; Kondadasula, SV; Kong, H; Kong, W; Kong, X; Kotidis, A; Kotwal, A; Kouvari, M; Kozhinov, AN; Kruger, D; Kuang, S; Kuang, Y; Kubota, M; Kuklik, P; Kumar, P; Kumar, SK; Kuo, YF; Kurup, SP; Kusuhara, H; Kuswanto, H; Lacouture, ME; Lambin, P; Lang, CC; Langroudi, FH; Lanman, RB; Larsen, OH; Laskin, J; Le, VH; Leach, M; Lee, BG; Lee, DF; Lee, DS; Lee, HJ; Lee, SB; Lee, YA; Lei, Y; Lekashvili, O; Lelj, F; Lemin, AS; Lemoine, J; Leuschner, R; Li, B; Li, BT; Li, C; Li, D; Li, F; Li, G; Li, H; Li, HW; Li, J; Li, M; Li, P; Li, Q; Li, S; Li, W; Li, X; Li, XY; Li, Y; Li, Z; Lian, Y; Liang, C; Liao, J; Liao, W; Liao, Y; Lin, D; Lin, W; Lin, YL; Lindbäck, J; Lindsay, AP; Ling, J; Linser, PJ; Liu, C; Liu, H; Liu, JJ; Liu, L; Liu, Q; Liu, SF; Liu, X; Liu, Y; Liu, Z; Liu, ZM; Lo Sterzo, C; Lo, ECM; Lobchuk, MM; Lodge, TP; Logotheti, S; Lonial, S; Lopes, G; Lopes, RD; Lopez, J; Lopez, SA; López-Santos, AL; López-Sendón, JL; Loring, Z; Louis, C; Lovita, AND; Lu, DZ; Lu, H; Lu, J; Lu, K; Lu, TT; Lu, Y; Luengo, A; Lum, LG; Luna, JM; Luo, L; Luo, R; Luo, T; Luo, X; Luo, Z; Lv, B; Lymperopoulos, N; Lyras, A; Lyu, Y; M Kannan, A; Ma, H; Ma, M; Ma, Q; Ma, S; Ma, WY; Ma, Y; Maalouf, E; Machado, FA; Maeda, K; Magrans, JO; Maharani, A; Maia, G; Mainwaring, RD; Maji, TK; Majumdar, K; Mannarino, MR; Mansuri, MS; Marinescu, SC; Markatos, G; Marquardt, S; Marraiki, N; Martens, C; Martínez, TJ; Marumo, K; Maruyama, H; Marwani, HM; Marzo, I; Masrati, G; Matamba, P; Mathialagan, S; Matys, J; Mayatra, JM; Mboua, PC; McArthur, T; McCrimmon, RJ; McIntosh, S; McSpadden, S; Medina-Campos, ON; Medvedovsky, AT; Mei, Z; Mekontso-Dessap, A; Menezes, AMB; Meng, J; Meng, P; Meng, Y; Menter, A; Mets, MB; Mets-Halgrimson, R; Metzger, T; Metzler-Nolte, N; Meyer, C; Mi, Y; Michailoviene, V; Mikrogeorgiou, A; Militz, H; Miller Iii, TF; Minarowska, A; Mir, S; Miron, I; Miyake, T; Moayer, F; Modi, S; Moeller, SJ; Mohamad, MN; Mohammed, EHM; Mokhonov, VV; Mondal, A; Moore, J; Moravcova, M; Mordi, IR; Mordi, NA; Mortensen, NP; Moscariello, C; Moser, J; Moynahan, ME; Mu, J; Mu, W; Mudduwa, LKB; Mukherjee, S; Mukhtar, A; Mulkey, DK; Murr, N; Mushtaq, Z; Muthuswamy, N; Mutlu, O; Muto, C; Myroforou, I; Na, KJ; Nabi, M; Nagornov, KO; Nagy, RJ; Naik, A; Nakajima, K; Nam, KT; Nam, YW; Namburath, M; Nammour, S; Namour, A; Namour, M; Nanan, S; Natsume, H; Nave, S; Naveed, A; Nazir, H; Ndubaku, C; Nedospasov, SA; Neradilek, MB; Newcomb, C; Nguépy Keubo, FR; Nguyen, M; Ning, J; Ning, Q; Noguchi, S; Nordahl, SHG; Nordfalk, KF; Norton, L; Noupoue, EM; Nouri, SS; Nowak, JK; Núñez, K; Oakes, K; Odegaard, JI; Ogorodnikova, OL; Ogunsuyi, O; Oh, HK; Oh, HR; Oh, KH; Ohgi, K; Okunade, KS; Oliveira, AG; Olorunfemi, G; Olsen, ML; Olson, BA; Omari, KW; Ondruschka, B; Orfali, R; Orkopoulos, A; Orlowski, RZ; Oser, SM; Oser, TK; Özcan, M; Padilla, V; Paeng, JC; Pajuelo-Lozano, N; Pal, SK; Palmieri, S; Palomeque, E; Pan, W; Panagiotakos, DB; Pandey, M; Pang, D; Pang, Q; Pangarah, CA; Panny, A; Paparella, A; Papirio, S; Papouskova, K; Parang, K; Park, HJ; Park, IK; Park, S; Parker, TL; Parkhomenko, A; Parmon, VN; Parsons, B; Parsons, J; Patel, PR; Patil, S; Patsourakos, NG; Patterson, KC; Pavlidis, P; Pedernera, M; Pedersen, R; Pedraza-Chaverri, J; Pellegrini, M; Peña-Chora, G; Pereira, EDM; Pereira, MADS; Peretz, A; Perez-Padilla, R; Perlman, GY; Perona, R; Petras, C; Phuntsho, S; Picada, JN; Pinder, TA; Piper, LFJ; Pirozzi, F; Pirro, M; Pleckaityte, M; Ploutz-Snyder, LL; Ploutz-Snyder, R; Pogorzelski, A; Poles, L; Postma, AA; Prager, A; Prakash, J; Punn, R; Pützer, BM; Qi, J; Qi, MC; Qi, Y; Qian, J; Qian, Y; Qiang, L; Qiu, J; Qu, Y; Rabiu, KA; Rahighi, S; Rahman, MM; Rahmani, B; Rajkumar, SV; Ramanathan, R; Raras, TYM; Rashi, Y; Rasool, G; Rathore, MG; Ratnawati, R; Ratola, N; Raucci, U; Ray, SK; Razavi, P; Razazi, K; Razek, S; Razi, SS; Reback, M; Reddy, K; Rees, DC; Reginatto, FH; Reich, H; Reis-Filho, JS; Ren, X; Ren, Y; Renner, G; Rey, G; Reymen, B; Riaz, M; Ricci, A; Richardson, PG; Richter, C; Riga, M; Ritchie, C; Rivoal, S; Roberts, W; Robson, ME; Rocha, GZ; Rodrigues, AD; Rogach, AL; Rojas, A; Rosenberg, A; Rosenberg, E; Rosenheck, RA; Roslan, K; Rothenberger, C; Rouschop, KMA; Rubagumya, F; Ryan, CM; Ryder, JW; Saad, MJA; Sacan, O; Sacchi, A; Sahebkar, A; Saini, A; Sainz, B; Sajo, EA; Sakizadeh, J; Saleh, AA; Salgado Júnior, IB; Salvi, R; Samoylova, YV; Samuni, A; Sanchez, DM; Sanchez-Perez, I; Santos, M; Sarapulova, A; Sardot, T; Saud, N; Sauerbier, P; Scaltriti, M; Schaeffer, B; Schalk, DL; Scherschel, K; Schijven, MP; Schreuder, HWR; Schuhmacher, M; Schultz-Lebahn, A; Schwarzl, J; Scott, JM; Sebayang, SK; Seeger, ZL; Segabinazi Peserico, C; Selenica, P; Serio, A; Seruga, B; Shah, A; Shah, C; Shah, PD; Shahrokh Tehraninezhad, E; Shan, A; Shao, Z; Sharma, AMR; Sharma, RK; Shen, J; Shen, R; Shi, X; Shi, Y; Shi, ZE; Shih, YC; Shimohata, H; Shimpi, N; Shin, SH; Shon, HK; Shuvy, M; Siddique, AB; Siegbahn, A; Sikandar, M; Silvani, Y; Singh, A; Singh, AK; Singh, D; Singh, JS; Singh, KP; Singh, M; Situ, B; Skipper, MT; Skouloudi, M; Sloane, BF; Smyrnioudis, N; Snyder, MA; Söhnchen, C; Solis Condor, R; Solit, DB; Someya, S; Song, H; Song, J; Song, W; Song, Y; Sorokina, KN; Soshi, S; Soyer, P; Spitschak, A; Sreekrishnan, TR; Srinivasan, M; Staruschenko, A; Steel, A; Stefan-van Staden, RI; Stein, AM; Strayer, H; Struthers, AD; Su, H; Su, Q; Su, X; Sudore, RL; Sugimura, H; Sugiyama, Y; Sujuti, H; Sumner, SJ; Sun, B; Sun, D; Sun, H; Sun, J; Sun, JY; Sun, X; Sun, Y; Sun, Z; Sung, YC; Surenaud, M; Sutimantanapi, D; Suwandaratne, NS; Swaroop, S; Sychrova, H; Syed, A; Szczepanik, M; Szederjesi, J; Szodorai, R; Tacy, TA; Tadelle, RM; Takayasu, M; Tammeveski, K; Tan, H; Tan, M; Tang, HX; Tang, S; Tang, X; Tanokura, M; Tao, F; Tao, H; Tarafdari, A; Tarín-Carrasco, P; Tasson Tatang, C; Teixeira, JP; Thakur, A; Theobald, A; Thevenot, P; Thomaidis, K; Tian, J; Tillib, SV; Toma, C; Tomita, M; Tonchev, I; Tong, F; Toy, W; Trypuć, M; Tselepis, AD; Tsetseris, L; Tsikouri, GE; Tsikouris, EI; Tsoplifack, CB; Tsoumani, ME; Tsujimoto, R; Tsybin, YO; Tu, J; Tu, TM; Turco, M; Turkyilmaz, IB; Uddin, MJ; Ung, J; Unsihuay, D; Utsunomiya, T; Vagenende, B; Vaishnav, J; Valdes, C; Validad, MH; Valle, J; van Ginkel, MPH; van Grevenstein, WMU; Vanderpuye, V; Vasan, N; Vasilenko, EA; Vasques, GJ; Vavoulis, P; Verani, A; Veziroglu, E; Viegas, A; Vitali, MG; Vitsas, G; Voccio, JP; Vogiatzidis, C; Volow, A; Volpin, F; Vourvahis, M; Wagner, LI; Walkowiak, J; Wallace, R; Wallentin, L; Wan, D; Wan, L; Wan, T; Wang, C; Wang, F; Wang, FN; Wang, H; Wang, J; Wang, L; Wang, Q; Wang, S; Wang, T; Wang, W; Wang, X; Wang, XW; Wang, Y; Wang, YS; Wang, Z; Ward, J; Ward, L; Waseem, R; Watson, DF; Weber, P; Wehrmeister, FC; Wei, CH; Wei, H; Wei, L; Wei, Q; Wei, Y; Weinstock, RS; Weiss, M; Welborn, M; Wen, L; Wen, LM; Wen, Q; Wen, Z; Wesseling, P; Westerbergh, J; White, K; Wick, MP; Willems, S; Wiyasa, IWA; Wójciak, R; Wolkenhauer, O; Won, HH; Wong, J; Woo, YC; Wood, LS; Wu, CT; Wu, CY; Wu, D; Wu, G; Wu, J; Wu, K; Wu, M; Wu, Q; Wu, T; Wu, W; Wu, X; Wu, XT; Wu, Y; Xi, D; Xi, J; Xiang, W; Xiang, Y; Xiao, M; Xiao, Z; Xie, H; Xie, Q; Xie, S; Xie, X; Xing, M; Xing, YL; Xu, C; Xu, X; Xu, Y; Xu, Z; Xue, F; Xue, XD; Yaglioglu, HG; Yamada, H; Yamashita, M; Yan, W; Yan, Z; Yanardag, R; Yang, D; Yang, H; Yang, K; Yang, QQ; Yang, R; Yang, S; Yang, T; Yang, X; Yang, Y; Yao, H; Yao, Y; Yari, D; Yassin, MT; Ye, C; Ye, J; Ye, Q; Yildiz, EA; Ying, S; Yoon, H; Yu, D; Yu, K; Yu, N; Yu, PL; Yuan, C; Yuan, D; Yuan, LJ; Yuan, Z; Yuen, N; Zagatto, AM; Zakaria, Y; Zalewski, AM; Zamora, S; Zavorotinskaya, T; Zeid, JL; Zeinoun, T; Zeng, C; Zerby, HN; Zhan, X; Zhang, A; Zhang, D; Zhang, E; Zhang, F; Zhang, H; Zhang, J; Zhang, L; Zhang, M; Zhang, P; Zhang, Q; Zhang, QY; Zhang, RG; Zhang, S; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, CK; Zhao, H; Zhao, J; Zhao, K; Zhao, Q; Zhao, S; Zhao, T; Zhao, XQ; Zhao, Y; Zhao, Z; Zheng, J; Zheng, L; Zheng, Y; Zhou, B; Zhou, G; Zhou, L; Zhou, T; Zhou, X; Zhu, C; Zhu, J; Zhu, Y; Zhu, ZQ; Zhuang, T; Zimmermannova, O; Zin, NNINM; Zisimos, K; Zoghebi, KA; Zonder, JA; Zou, C; Zwirner, J1
Anker, SD; Bocchi, E; Böhm, M; Brueckmann, M; Brunner-La Rocca, HP; Butler, J; Carson, P; Choi, DJ; Chopra, V; Chuquiure, E; Cotton, D; Filippatos, G; Giannetti, N; Gonzalez Juanatey, JR; Jamal, W; Janssens, S; Januzzi, J; Kaul, S; Kimura, K; Merkely, B; Nicholls, SJ; Packer, M; Perrone, S; Pina, I; Pocock, SJ; Ponikowski, P; Sattar, N; Schnee, J; Senni, M; Seronde, MF; Spinar, J; Squire, I; Taddei, S; Tsutsui, H; Verma, S; Wanner, C; Zannad, F; Zeller, C; Zhang, J1
Asseburg, C; Brennan, A; Clarke, PM; Feenstra, T; Gray, A; Herman, WH; Isaman, DJ; Kuo, S; Lamotte, M; Leal, J; McEwan, P; Nilsson, A; Palmer, AJ; Patel, R; Pollard, D; Ramos, M; Sailer, F; Schramm, W; Shao, H; Shi, L; Si, L; Smolen, HJ; Tew, M; Willis, MS; Ye, W; Zhang, P1
Chertow, GM; Correa-Rotter, R; Greene, T; Heerspink, HJL; Hou, FF; Langkilde, AM; Lindberg, M; Mann, JFE; McMurray, JJV; Rossing, P; Sjöström, CD; Stefánsson, BV; Toto, RD; Wheeler, DC1
George, JT; Hantel, S; Koitka-Weber, A; Levin, A; Perkovic, V; von Eynatten, M; Wanner, C; Wheeler, DC1
Jiang, XY; Qu, Q; Sun, JY; Tang, C; Wang, ZY; Zheng, XD1
Eliasson, B; Inzucchi, SE; Johansen, OE; Kasai, T; Marx, N; Neeland, IJ; Wanner, C; Wojeck, BS; Yaggi, HK; Zinman, B; Zwiener, I1
Agarwala, A; Al Rifai, M; Hussain, A; Jia, X; Martin, S; Virani, SS1
Hui, Y; Xu, Y; Yang, C; Yin, D1
Doumas, M; Imprialos, K; Papadopoulos, C; Patoulias, D; Stavropoulos, K1
Ceriello, A; George, J; Kaspers, S; Nicolucci, A; Ofstad, AP; Zwiener, I1
Khong, TK; Magavern, E1
Haynes, R; Judge, PK1
Anker, SD; Bocchi, EA; Böhm, M; Brueckmann, M; Butler, J; Ferreira, JP; Filippatos, G; Jamal, W; Januzzi, JL; Khan, MS; Lam, CSP; Marx, N; Ofstad, AP; Packer, M; Perrone, SV; Pocock, SJ; Ponikowski, P; Schnaidt, S; Verma, S; Zannad, F1
Chertow, GM; Correa-Rotter, R; Greene, T; Heerspink, HJL; Held, C; Hou, FF; Jongs, N; Langkilde, AM; Mann, JFE; McMurray, JJV; Postmus, D; Rossing, P; Sjöström, CD; Stefánsson, BV; Toto, RD; Wheeler, DC1
Aroda, VR; Sabatine, MS1
Khunti, K1
Cauchon, M; Lanthier, L; Masse, M; Plourde, MÉ1
Ambery, P; Berwanger, O; Buenconsejo, J; Chopra, V; Esterline, R; Gasparyan, SB; Javaheri, A; Koch, GG; Kosiborod, M; Langkilde, AM; Martinez, F; Mukhtar, O; Oscarsson, J; Sjöström, CD; Verma, S1
Chertow, GM; Correa-Rotter, R; Greene, T; Heerspink, HJL; Hou, FF; Jongs, N; Langkilde, AM; McMurray, JJV; Rossing, P; Sjöström, CD; Stefánsson, BV; Toto, RD; Wheeler, DC1
Tuttle, KR1
Nabavizadeh, P; Steen, DL1
Altiok, E; Böhm, M; Hartmann, NK; Keszei, AP; Lehrke, M; Marx, N; Möllmann, J; Rau, M; Schuh, A; Thiele, K1
Hirose, T; Hiruma, S; Hisatake, S; Hori, M; Ikeda, T; Kumashiro, N; Mizumura, S; Shigiyama, F; Shiraga, N1
Cessario, J; Li, Z; Pierre-Louis, V; Wahl, J1
Bengtsson, O; Berg, DD; Docherty, KF; Inzucchi, SE; Jhund, PS; Kosiborod, MN; Køber, L; Langkilde, AM; Martinez, FA; McMurray, JJV; Murphy, SA; Ponikowski, P; Sabatine, MS; Sjöstrand, M; Solomon, SD; Verma, S1
Diogo, V; Gourzoulidis, G; Ioannidis, I; Karpouzos, G; Kourlaba, G; Papageorgiou, G; Tsimihodimos, V; Tzanetakos, C1
Li, N; Li, SY; Tian, HM; Wang, MY; Zhang, R; Zhang, YG; Zhou, YL1
Ferreira, JP; Fitchett, DH; George, JT; Koitka-Weber, A; Kraus, BJ; Lauer, S; Ofstad, AP; Wanner, C; Zannad, F; Zinman, B; Zwiener, I1
Ali, S; Brojen Singh, RK; Lebeche, D; Mangangcha, IR1
Chertow, GM; Correa-Rotter, R; Heerspink, HJL; Hou, FF; Jongs, N; Kosiborod, M; Kurlyandskaya, R; Langkilde, AM; McMurray, JJV; Rossing, P; Sjöström, CD; Stefansson, BV; Toto, RD; Wheeler, DC1
Bhatt, DL; Cahn, A; Dwyer, JP; Gause-Nilsson, I; Goodrich, EL; Heerspink, HHJL; Im, K; Langkilde, AM; Leiter, LA; McGuire, DK; Mosenzon, O; Raz, I; Sabatine, MS; Wilding, JPH; Wiviott, SD; Zelniker, TA1
Brand, SB; Cragin, L; Fahrbach, K; Gandhi, PK; Kansal, AR; Pfarr, E; Reifsnider, OS; Ustyugova, A1
Chen, R; Fan, G; Wu, XY; Yi, H; Zhao, CC1
Abushanab, D; Ademi, Z; Al-Badriyeh, D; Liew, D1
Booz, GW; Fan, F; Jiao, F; Liu, R; Liu, Y; Roman, RJ; Varghese, K; Wang, S; Yu, H1
Ang, L; Dillon, B; Fang, F; Kidwell, KM; Leone, V; Mizokami-Stout, K; Pop-Busui, R; Reiss, J1
Baggesen, LM; Holmgaard, PH; Kahlert, J; Knudsen, JS; Lajer, M; Sørensen, HT; Thomsen, RW; Ustyugova, A; Vedin, O1
Fitchett, D; George, J; Inzucchi, SE; Kosiborod, MN; Leiter, LA; Mattheus, M; Ofstad, AP; Sharma, A; Verma, S; Wanner, C; Zinman, B1
Higashi, Y; Node, K; Okada, Y; Shimabukuro, M; Taguchi, I; Takamura, T; Tanaka, A; Teragawa, H; Tomiyama, H; Toyoda, S; Ueda, S2
Bajaj, HS; Chertow, GM; Correa-Rotter, R; Heerspink, HJL; Hou, FF; Jongs, N; Langkilde, AM; McMurray, JJV; Persson, F; Rossing, P; Stefansson, BV; Toto, RD; Vart, P; Wheeler, DC1
Chou, TW; Jhuo, SJ; Lai, WT; Lee, KT; Lin, YH; Liu, IH; Tasi, WC; Wu, BN1
Doi, T; Hirata, KI; Matsumoto, K; Mochizuki, Y; Sano, H; Shite, J; Soga, F; Takaoka, H; Tanaka, H; Tatsumi, K; Toki, H1
Anker, SD; Bocchi, E; Böhm, M; Brueckmann, M; Brunner-La Rocca, HP; Butler, J; Carson, P; Choi, DJ; Chopra, V; Chuquiure-Valenzuela, E; Ferreira, JP; Filippatos, G; Giannetti, N; Gomez-Mesa, JE; Gonzalez-Juanatey, JR; Jamal, W; Janssens, S; Januzzi, JL; Lam, CSP; Marx, N; Merkely, B; Nicholls, SJ; Packer, M; Perrone, SV; Piña, IL; Pocock, SJ; Ponikowski, P; Sattar, N; Schnaidt, S; Schnee, JM; Senni, M; Sim, D; Spinar, J; Squire, I; Taddei, S; Tsutsui, H; Verma, S; Vinereanu, D; Zannad, F; Zeller, C; Zhang, J1
Cheng, KK; Ghosh, S; Gokhale, K; Hanif, W; Kumarendran, B; Marshall, T; Narendran, P; Nirantharakumar, K; Thomas, GN; Toulis, KA; Willis, BH1
Aschenbrenner, DS1
Eriksson, JW; Johnsson, E; Katsogiannos, P; Lundkvist, P; Pereira, MJ; Sjöström, CD1
Krzesinski, JM; Paquot, N; Piérard, L; Scheen, AJ1
Albers, GW; Broedl, UC; Diener, HC; Fitchett, D; Inzucchi, SE; Johansen, OE; Kohler, S; Lachin, JM; Mattheus, M; Wanner, C; Woerle, HJ; Zinman, B1
Bain, S; Chudleigh, RA1
Avogaro, A; Bonora, E; Colivicchi, F; Ferrannini, E; Fioretto, P; Maggioni, AP; Perrone-Filardi, P; Sesti, G1
Ahn, YB; Cha, SA; Ko, SH; Lim, TS; Park, YM; Song, KH; Yoo, KD; Yun, JS1
Avogaro, A; Del Prato, S; Fioretto, P; Genovese, S; Giaccari, A; Giorgino, F; Purrello, F1
Jaffa, FM; Johnson, E; Kalyani, RR; Shubrook, JH; Skolnik, N1
Palau, V; Riera, M; Soler, MJ1
Wanner, C2
Chilton, R1
Chilton, R; Pham, SV1
Staels, B2
Perreault, L2
Chen, KJ; Cong, WH; Guo, G; Hu, YJ; Lee, SM; Liao, QW; Wang, Y; Xin, QQ; Yang, BR1
Eleftheriadou, I; Grigoropoulou, P; Kokkinos, A; Liatis, S; Liberopoulos, E; Tentolouris, N1
Burggraaf, B; Castro Cabezas, M1
Amadid, H; Færch, K; Jørgensen, ME; Karstoft, K; Nielsen, LB; Persson, F; Ried-Larsen, M1
Chilton, RJ1
Chilton, RJ; Pham, SV1
Kaul, S1
Abdul-Ghani, M; Chilton, R; DeFronzo, RA; Del Prato, S; Ryder, REJ; Singh, R1
Cherney, DZI; Inzucchi, SE; Koitka-Weber, A; Mattheus, M; von Eynatten, M; Wanner, C; Zinman, B1
Ernest, P; Jandrain, B; Scheen, AJ; Wallemacq, C1
Drexler, A1
Jabbour, S1
Gürke, L; Tampaki, EC; Tampakis, A2
Diener, HC; Inzucchi, SE; Zinman, B1
Birkeland, KI; Bodegard, J; Carstensen, B; Eriksson, JW; Fenici, P; Gulseth, HL; Jørgensen, ME; Nathanson, D; Norhammar, A; Nyström, T; Persson, F; Thuresson, M2
Black, RL; Irons, BK; Minze, MG; Terrell, BT; Will, KJ1
Athyros, VG; Doumas, M; Imprialos, KP; Karagiannis, A; Stavropoulos, K1
Adamski, J; Artati, A; Kappel, BA; Lebherz, C; Lehrke, M; Marx, N; Schütt, K1
Jumar, A; Kannenkeril, D; Karg, MV; Ott, C; Schmieder, RE; Schneider, MP; Striepe, K1
Chen, YQ; Deng, XJ; Li, D; Song, F; Ya, FL; Yang, Y; Zhang, XD; Zhou, FH1
Butler, J; Fitchett, D; George, JT; Hantel, S; Inzucchi, SE; Johansen, OE; Lachin, JM; van de Borne, P; Wanner, C; Woerle, HJ; Zinman, B1
Bell, RM; Yellon, DM1
Al-Omran, M; Fitchett, D; George, JT; Hehnke, U; Inzucchi, SE; Mazer, CD; Verma, S; Zinman, B1
Coleman, CI; Nair, S; Nguyen, E; Weeda, ER1
Bluhmki, E; Ferrannini, E; Fitchett, D; George, JT; Hantel, S; Inzucchi, SE; Johansen, OE; Lachin, JM; Ohneberg, K; Schmoor, C; Schumacher, M; Wanner, C; Zinman, B1
Suissa, S1
Bakris, G; Plutzky, J1
Bhatt, DL; Bonaca, MP; Cahn, A; Gause-Nilsson, IAM; Johansson, PA; Kato, ET; Langkilde, AM; Leiter, LA; McGuire, DK; Mosenzon, O; Raz, I; Sabatine, MS; Silverman, MG; Wilding, JPH; Wiviott, SD1
Broedl, UC; Fitchett, D; George, JT; Inzucchi, SE; Johansen, OE; Lachin, JM; Mattheus, M; van de Borne, P; Wanner, C; Woerle, HJ; Zinman, B1
Gourzoulidis, G; Ioannidis, I; Kourlaba, G; Maniadakis, N; Papageorgiou, G; Tsapas, A; Tzanetakos, C1
Paquot, N; Scheen, AJ1
Eckel, RH; Koh, KK; Lim, S1
Chang, J; Goyat, R; Ponte, CD; Rai, P; Tan, X1
Bell, KF; Enhoffer, DM; Eudicone, JM; Green, JB; Latham, K; Wittbrodt, ET1
Duong, J; Herman, WH; Kuo, S; Ye, W1
Cherney, DZI; Heerspink, HJL; Inzucchi, SE; Kosiborod, M1
Fitchett, D; George, JT; Inzucchi, SE; Mazer, CD; Pfarr, E; Verma, S; Zinman, B1
Leiter, LA; Lingvay, I1
Ren, DY; Zhang, Y1
Akiyama, N; Kashiwagi, A; Kazuta, K; Kosakai, Y; Nakamura, I; Sakatani, T; Takahashi, H; Ueyama, E1
Fuchigami, A; Hirose, T; Kumashiro, N; Shigiyama, F1
Frampton, JE1
De Ponti, F; Fadini, GP; Marchesini, G; Poluzzi, E; Raschi, E1
Arbel, R; Azuri, J; Hammerman, A1
Inzucchi, SE; Lupsa, BC1
Marx, N; Wanner, C1
Goldman, JD1
Jakupović, L; Javor, E; Lucijanić, M; Lucijanić, T; Rahelić, D; Skelin, M1
Claggett, B; Fitchett, D; George, JT; Hantel, S; Inzucchi, SE; Lachin, JM; Woerle, HJ; Zinman, B1
Fitchett, D; George, JT; Hehnke, U; Inzucchi, SE; Kaspers, S; Kosiborod, M; Wanner, C; Zinman, B1
Koh, KK1
von Eynatten, M; Wanner, C; Zinman, B1
Hantel, S; Kadowaki, T; Koitka-Weber, A; Nangaku, M; Okamura, T; von Eynatten, M; Wanner, C1
Bhatt, DL; Bonaca, MP; Cahn, A; Fredriksson, M; Gause-Nilsson, IAM; Johansson, PA; Kato, ET; Kuder, JF; Langkilde, AM; Leiter, LA; McGuire, DK; Mosenzon, O; Murphy, SA; Raz, I; Ruff, CT; Sabatine, MS; Silverman, MG; Wilding, JPH; Wiviott, SD; Zelniker, TA1
Dong, P; Liu, H; Zhao, D1
Bookhart, B; Cai, J; Durkin, M; Kamstra, R; Lafeuille, MH; Lefebvre, P; Manceur, AM; Pilon, D; Tiggelaar, S1
Bodegård, J; Eriksson, JW; Nathanson, D; Norhammar, A; Nyström, T; Thuresson, M2
Åkerblom, A; Johansson, L; Karlsson, C; Latva-Rasku, A; Lisovskaja, V; Nuutila, P; Oldgren, J; Oscarsson, J1
Abdul Rashid, AM; Adams, L; Agah, R; Ahmad Saad, FF; Akay, S; Appiah-Opong, R; Aronson, RD; Asbun, H; Ashong, Y; Ayi, I; Baez, P; Bar-Ad, V; Bay, JL; Bello-Pagan, M; Blackbourn, LAK; Bolan, C; Brierley, L; Cannaday, S; Cannon, TL; Caparrotta, TM; Capitano, M; Colhoun, HM; Coppola, D; Crees, ZD; Crites, D; Devaraj, K; Dumashie, E; Edil, BH; Endo, K; Ferrone, CR; Forcione, DG; Ford, J; Fortuna, D; Garcia, M; Gilad, GM; Gomez, V; Gonzalez, C; Gwira, TM; Han, JY; Hanaki, T; Hardacre, JM; Hester, D; Hidalgo, M; Hirschler, V; Hodul, PJ; Ikeguchi, M; Intersimone, P; Jang, JH; Ji, Z; Johnson, T; Kandel, P; Koh, R; Lee, G; Lee, IG; Leese, GP; Li, J; Liu, X; Lopez, MJ; Maccallini, G; Macdonald, DB; Malek, R; Maley, WR; Martel, G; McCrimmon, RJ; McGurnaghan, SJ; McKeigue, PM; McKnight, JA; Md Noh, MSF; Miao, Y; Mody, K; Molinari, C; Monroe, JF; Mora, HA; Morton, SM; Moyana, TN; Munoz-Jordan, J; Nakamura, S; Neaterour, P; Orcutt, ST; Palmer, JD; Paniccia, A; Park, J; Pearson, ER; Perez, NP; Petrie, JR; Pyatibrat, S; Rademacher, N; Raimondo, M; Ranasinha, N; Reyes, N; Richardson, LC; Ritter, AW; Rivera, A; Rivera-Garcia, B; Rosemurgy, AS; Ross, SB; Sama, A; Sattar, N; Sawata, T; Schulick, RD; Shang, D; Sharp, TM; Shimizu, T; Şirin, B; Sloboda, DM; So, E; Song, X; Srour, SA; Stauffer, J; Suzuki, K; Taguchi, T; Takawira, C; Torphy, R; Trump, DL; Tuffour, I; Ünsal, B; Van Dyne, EA; Vickers, MH; Vitulli, PL; Wallace, MB; Wang-Gillam, A; Waterman, SH; Wei, J; Weinstein, JC; Wild, SH; Williams, N; Winter, J; Woodward, TA; Wu, ES; Wu, J; Yeo, CJ; Yeo, TP; Yeung, V; Zhang, JB1
Aharon-Hananel, G; Raz, I1
Abbas, J; Atkin, SL; Deshmukh, H; Javed, Z; Khan, AY; Kilpatrick, ES; Papageorgiou, M; Qamar, U; Rigby, AS; Sathyapalan, T1
Kaneko, M; Narukawa, M1
Bengtsson, O; DeMets, DL; Inzucchi, SE; Kosiborod, MN; Køber, L; Langkilde, AM; Martinez, FA; McMurray, JJV; Ponikowski, P; Sabatine, MS; Sjöstrand, M; Solomon, SD1
De Ponti, F; Marchesini, G; Poluzzi, E; Raschi, E1
Scheen, AJ6
Al Rifai, M; Al-Mallah, MH; Jia, X; Martin, SS; Miedema, MD; Virani, SS1
Aliani, M; Austria, JA; Maddaford, TG; Netticadan, T; Parikh, M; Pierce, GN1
Cherney, DZI; Hantel, S; Inzucchi, SE; Koitka-Weber, A; Mayer, GJ; von Eynatten, M; Wanner, C; Weir, MR; Zinman, B1
Davis, SN; Hedrington, M; Lamos, EM1
Brueckmann, M; Butler, J; Cheung, AK; Fitchett, D; George, J; Koitka-Weber, A; von Eynatten, M; Wanner, C; Zannad, F; Zinman, B; Zwiener, I1
Rothenberg, F; Schacht, S; Thompson, J1
Cobble, ME; Kluger, AY; Lee, AY; Lepor, NE; Lerma, EV; McCullough, PA; Rangaswami, J; Tecson, KM1
Anthony, S; Bajwa, H; Peter, R1
Horng, LY; Hsu, PL; Peng, KY; Sung, HC; Wu, CL; Wu, RT1
Hardy, E; Johnsson, E; List, J; Parikh, S; Ptaszynska, A1
de Zeeuw, D; Desai, M; Fulcher, G; Jiang, J; Mahaffey, KW; Matthews, D; Meininger, G; Neal, B; Perkovic, V; Shaw, W; Stein, P; Vercruysse, F1
Alperin, P; Cohen, M; Dziuba, J; Goswami, D; Grossman, HL; Hardy, E; Iloeje, U; Perlstein, I; Racketa, J1
Cefalu, WT; de Bruin, TW; Gause-Nilsson, I; Leiter, LA; Parikh, SJ; Sugg, J1
Bluhmki, E; Broedl, UC; Ferrari, R; Fitchett, D; Hantel, S; Inzucchi, SE; Johansen, OE; Kempthorne-Rawson, J; Lachin, JM; Newman, J; Wanner, C; Woerle, HJ; Zinman, B1
Bennett, H; Bergenheim, K; McEwan, P; Ward, T1
Hasegawa, Y; Kim-Mitsuyama, S; Koibuchi, N; Kusaka, H; Lin, B; Ma, M; Nakagawa, T; Sueta, D; Toyama, K; Uekawa, K1
Heneghan, CJ; Onakpoya, IJ1
Andrenacci, E; Biscaglia, S; Campo, G; Ferrari, R; Ferri, A; Pavasini, R; Tebaldi, M1
Alameddine, A; Ayer, A; Bourreau, J; Custaud, MA; Derbre, S; Fajloun, Z; Gauguier, D; Gauquelin-Koch, G; Navasiolava, N; Yuan, M1
Bluhmki, E; Broedl, UC; Devins, T; Fitchett, D; Hantel, S; Inzucchi, SE; Johansen, OE; Lachin, JM; Mattheus, M; Wanner, C; Woerle, HJ; Zinman, B1
Muskiet, MH; Smits, MM; Tonneijck, L; van Bommel, E; van Bommel, EJ; van Raalte, DH1
Ceriello, A; Genovese, S; Gronda, E; Mannucci, E1
Connelly, KA; Gilbert, RE1
Basu, S; Naci, H; Yudkin, JS1
Ingelfinger, JR; Rosen, CJ2
Malhotra, S; Shafiq, N1
McGuire, DK; Neeland, IJ; Salahuddin, U1
Overbeck, P1
Shekelle, P1
Gause-Nilsson, I; Johansson, PA; Johnsson, E; Sonesson, C1
Abdul-Ghani, M; Chilton, R; Clarke, G; DeFronzo, RA; Norton, L; Ryder, RE1
Maltezos, ES; Papanas, N; Tsioufis, C1
Ebell, MH1
Einecke, D1
Zechmann, S1
Inzucchi, SE; Lachin, JM; Zinman, B1
Sarafidis, PA; Tsapas, A1
Edwards, JL1
Fischereder, M; Schönermarck, U1
Hough, A; Rosenstein, R1
Müller-Wieland, D1
Bloomgarden, Z1
Blomster, J; Foote, C; Neal, B; Perkovic, V; Sundström, J; Toyama, T; Wu, JH1
Cefalu, WT; de Bruin, TW; Gause-Nilsson, I; Johnsson, E; Leiter, LA; Parikh, S; Xu, J1
Bandyopadhyay, D; Biswas, M; Ghosh, RK; Gupta, A; Hajra, A1
Kawai, T; Meguro, S; Sano, M; Suzuki, Y1
Mellbin, L; Rydén, L; Shahim, B1
Kristensen, SL; McLaren, J; McMurray, JJ; Preiss, D; Sattar, N1
Stiefelhagen, P1
Gupta, Y; Kalra, S; Kishor, K1
Bondonno, CP; Bondonno, NP; Croft, KD; Hodgson, JM; Mas, E; Rich, L; Shinde, S; Ward, NC1
Laubner, K; Seufert, J1
Abdul-Ghani, M; Chilton, R; DeFronzo, RA; Del Prato, S1
Schernthaner, G; Schernthaner, GH; Schernthaner-Reiter, MH1
Perseghin, G; Solini, A1
Arnheim, K1
Alloju, S; Henry, RR; Mudaliar, S1
Ferrannini, E; Mark, M; Mayoux, E1
Broedl, UC; Fitchett, D; Inzucchi, SE; Johansen, OE; Lachin, JM; Mattheus, M; von Eynatten, M; Wanner, C; Woerle, HJ; Zinman, B1
Fioretto, P; Johnsson, E; Mansfield, TA; Parikh, S; Ptaszynska, A; Yavin, Y1
Bonadonna, RC; Borghi, C; Consoli, A; Volpe, M1
Broedl, UC; Hantel, S; Kim, G; Salsali, A; Woerle, HJ1
Preiss, D; Sattar, N1
Busetto, L; Fioretto, P; Rossato, M; Vettor, R; Zambon, A1
Dicembrini, I; Mannucci, E; Monami, M1
Grant, PJ1
Hernández, C; Simó, R1
Muskiet, MH; Smits, MM; Tonneijck, L; van Bommel, EJ; van Raalte, DH1
Dalama, B; Mesa, J1
Khandelwal, S; Naing, S; Poliyedath, A; Sigala, T1
Di Franco, A; Luconi, M; Mannucci, E; Raimondi, L1
Cusi, K1
Inzucchi, SE; Stamatouli, AM1
Rossello, X; Yellon, DM1
Close, KL; Dove, AE; Gao, HX; Marathe, PH; Odeh, SA1
Boutari, C; Doumas, M; Imprialos, KP; Karagiannis, AI; Stavropoulos, K1
George, J; Kaku, K; Kaspers, S; Lee, J; Mattheus, M; Woerle, HJ1
Koya, D1
Node, K; Tanaka, A1
Rajput, R; Ved, J1
Fioretto, P; Inzucchi, SE; Vettor, R1
Nuffer, WA; Trujillo, JM1
Lazaridis, AA; Ruilope, LM; Ruiz-Hurtado, G; Sarafidis, PA1
Bando, YK; Murohara, T1
Fiorentino, TV; Sesti, G1
Kramer, MHH; Muskiet, MHA; Nieuwdorp, M; Tonneijck, L; van Bommel, EJM; van Raalte, DH1
Turner, JR1
Avogaro, A; Fioretto, P1
Alzaid, A1
Adolphe, JL; Alcorn, J; Juurlink, BH; Thorpe, LU; Whiting, SJ1
Wick, JY1
Andrews, MC; Chen, P; Jin, JW; Li, C; Ling, W; Ni, H; Reheman, A; Shi, Z; Wang, Y; Yang, Y; Zhu, G1
de BUMAN, M1
Gibbins, JM; Hubbard, GP; Lovegrove, JA; Wolffram, S1
Samilova, RD1
Hollman, PC; Katan, MB; Olthof, MR; Zock, PL1

Reviews

79 review(s) available for glucose, (beta-d)-isomer and Cardiovascular Diseases

ArticleYear
Preventing cardiovascular heart disease: Promising nutraceutical and non-nutraceutical treatments for cholesterol management.
    Pharmacological research, 2017, Volume: 120

    Topics: Animals; Anticholesteremic Agents; Biological Products; Cardiovascular Diseases; Dietary Supplements; Humans; Hypercholesterolemia; Risk Factors; Zymosan

2017
The anti-hypertensive effects of sodium-glucose cotransporter-2 inhibitors.
    Expert review of cardiovascular therapy, 2023, Volume: 21, Issue:1

    Topics: Antihypertensive Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucose; Glucosides; Humans; Hypertension; Hypoglycemic Agents; Sodium; Sodium-Glucose Transporter 2 Inhibitors

2023
Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes.
    Advances in therapy, 2019, Volume: 36, Issue:10

    Topics: Benzhydryl Compounds; Blood Glucose; Canagliflozin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Glucosides; Hospitalization; Humans; Hypoglycemic Agents; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors

2019
Effect of empagliflozin beyond glycemic control: Cardiovascular benefit in patients with type 2 diabetes and established cardiovascular disease.
    Revista portuguesa de cardiologia, 2019, Volume: 38, Issue:10

    Topics: Benzhydryl Compounds; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Sodium-Glucose Transporter 2 Inhibitors

2019
Dapagliflozin and cardiovascular outcomes in patients with Type 2 diabetes.
    Future cardiology, 2020, Volume: 16, Issue:2

    Topics: Benzhydryl Compounds; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors

2020
SGLT-2 inhibitors in diabetes: a focus on renoprotection.
    Revista da Associacao Medica Brasileira (1992), 2020, Jan-13, Volume: 66Suppl 1, Issue:Suppl 1

    Topics: Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glomerular Filtration Rate; Glucose; Glucosides; Humans; Hypoglycemic Agents; Kidney; Kidney Diseases; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors

2020
Translating the statistical benefits of SGLT-2 inhibitors on cardio-renal outcomes into clinical practice.
    Expert review of clinical pharmacology, 2020, Volume: 13, Issue:5

    Topics: Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors

2020
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acrylic Resins; Actinobacillus; Acute Disease; Acute Kidney Injury; Adaptor Proteins, Signal Transducing; Adenosine; Adenosine Triphosphate; Administration, Inhalation; Administration, Oral; Adolescent; Adult; Advance Care Planning; Africa, Northern; Age Factors; Aged; Aged, 80 and over; Air Pollutants; Air Pollution; Air Pollution, Indoor; Albendazole; Aluminum Oxide; Anastomosis, Surgical; Ancylostoma; Ancylostomiasis; Androstadienes; Angiogenesis Inhibitors; Angiotensin II; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bispecific; Antibodies, Viral; Anticoagulants; Antihypertensive Agents; Antinematodal Agents; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antiporters; Antiviral Agents; Apoptosis; Aptamers, Nucleotide; Aromatase Inhibitors; Asian People; Astrocytes; Atrial Fibrillation; Auditory Threshold; Aurora Kinase B; Australia; Autophagy; Autophagy-Related Protein 5; Autotrophic Processes; Bacillus cereus; Bacillus thuringiensis; Bacterial Proteins; Beclin-1; Belgium; Benzene; Benzene Derivatives; Benzhydryl Compounds; beta Catenin; beta-Arrestin 2; Biliary Tract Diseases; Biofilms; Biofuels; Biomarkers; Biomarkers, Tumor; Biomass; Biomechanical Phenomena; Bioreactors; Biosensing Techniques; Biosynthetic Pathways; Bismuth; Blood Platelets; Bone and Bones; Bone Regeneration; Bortezomib; Botulinum Toxins, Type A; Brain; Brain Injuries; Brain Ischemia; Brain Neoplasms; Breast Neoplasms; Breath Tests; Bronchodilator Agents; Calcium Phosphates; Cannabis; Carbon Dioxide; Carbon Isotopes; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cardiac Resynchronization Therapy; Cardiac Resynchronization Therapy Devices; Cardiomyopathies; Cardiovascular Diseases; Cariostatic Agents; Case Managers; Case-Control Studies; Catalysis; Cation Transport Proteins; CD8-Positive T-Lymphocytes; Cecropia Plant; Cell Adhesion; Cell Count; Cell Differentiation; Cell Division; Cell Line; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Self Renewal; Cell Survival; Cells, Cultured; Cellular Reprogramming; Cellulose; Charcoal; Chemical and Drug Induced Liver Injury; Chemical Phenomena; Chemokines; Chemoradiotherapy; Chemoreceptor Cells; Child; Child Abuse; Child, Preschool; China; Chlorogenic Acid; Chloroquine; Chromatography, Gas; Chronic Disease; Clinical Competence; Coated Materials, Biocompatible; Cochlea; Cohort Studies; Color; Comorbidity; Computer Simulation; Computer-Aided Design; Contraception; Contraceptive Agents, Female; Contrast Media; COP-Coated Vesicles; Coronavirus Infections; Cost of Illness; Coturnix; COVID-19; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Culex; Curriculum; Cyclic N-Oxides; Cytokines; Cytoplasm; Cytotoxicity, Immunologic; Cytotoxins; Databases, Factual; Deep Learning; Delivery, Obstetric; Denitrification; Dental Caries; Denture, Complete; Dexamethasone; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dielectric Spectroscopy; Diet, High-Fat; Dietary Fiber; Disease Models, Animal; Disease Progression; DNA; DNA Copy Number Variations; DNA, Mitochondrial; Dog Diseases; Dogs; Dopaminergic Neurons; Double-Blind Method; Down-Regulation; Doxorubicin; Drug Carriers; Drug Design; Drug Interactions; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Drugs, Chinese Herbal; Dry Powder Inhalers; Dust; E2F1 Transcription Factor; Ecosystem; Education, Nursing; Education, Nursing, Baccalaureate; Electric Impedance; Electricity; Electrocardiography; Electrochemical Techniques; Electrochemistry; Electrodes; Electrophoresis, Polyacrylamide Gel; Endoplasmic Reticulum; Endothelial Cells; Environmental Monitoring; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Estrogen Receptor Modulators; Europe; Evoked Potentials, Auditory, Brain Stem; Exosomes; Feasibility Studies; Female; Ferricyanides; Ferrocyanides; Fibrinogen; Finite Element Analysis; Fistula; Fluorescent Dyes; Fluorides, Topical; Fluorodeoxyglucose F18; Fluticasone; Follow-Up Studies; Food Contamination; Food Microbiology; Foods, Specialized; Forensic Medicine; Frail Elderly; France; Free Radicals; Fresh Water; Fungi; Fungicides, Industrial; Galactosamine; Gastrointestinal Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Frequency; Genetic Predisposition to Disease; Genotype; Gingival Hemorrhage; Glioblastoma; Glioma; Glomerular Filtration Rate; Glomerulosclerosis, Focal Segmental; Glucose; Glucose Transport Proteins, Facilitative; Glucosides; Glutamine; Glycolysis; Gold; GPI-Linked Proteins; Gram-Negative Bacteria; Gram-Positive Bacteria; Graphite; Haplotypes; HCT116 Cells; Healthy Volunteers; Hearing Loss; Heart Failure; Hedgehog Proteins; HEK293 Cells; HeLa Cells; Hemodynamics; Hemorrhage; Hepatocytes; Hippo Signaling Pathway; Histone Deacetylases; Homeostasis; Hospital Mortality; Hospitalization; Humans; Hydantoins; Hydrazines; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Hydroxylamines; Hypoglycemic Agents; Immunity, Innate; Immunoglobulin G; Immunohistochemistry; Immunologic Factors; Immunomodulation; Immunophenotyping; Immunotherapy; Incidence; Indazoles; Indonesia; Infant; Infant, Newborn; Infarction, Middle Cerebral Artery; Inflammation; Injections, Intramuscular; Insecticides; Insulin-Like Growth Factor I; Insurance, Health; Intention to Treat Analysis; Interleukin-1 Receptor-Associated Kinases; Interleukin-6; Intrauterine Devices; Intrauterine Devices, Copper; Iron; Ischemia; Jordan; Keratinocytes; Kidney; Kidney Diseases; Kir5.1 Channel; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Laparoscopy; Lasers; Lasers, Semiconductor; Lenalidomide; Leptin; Lethal Dose 50; Levonorgestrel; Limit of Detection; Lipid Metabolism; Lipid Metabolism Disorders; Lipogenesis; Lipopolysaccharides; Liquid Biopsy; Liver; Liver Abscess, Pyogenic; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Longevity; Lung Neoplasms; Luteolin; Lymph Nodes; Lymphocyte Activation; Macaca fascicularis; Macrophages; Mad2 Proteins; Magnetic Resonance Imaging; Male; Mammary Glands, Human; Manganese; Manganese Compounds; MAP Kinase Signaling System; Materials Testing; Maternal Health Services; MCF-7 Cells; Medicaid; Medicine, Chinese Traditional; Melanoma; Membrane Proteins; Mental Health; Mercury; Metal Nanoparticles; Metals, Heavy; Metformin; Methionine Adenosyltransferase; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Knockout; Mice, Nude; Microalgae; Microbial Sensitivity Tests; Microglia; MicroRNAs; Microscopy, Atomic Force; Microscopy, Electron, Scanning; Middle Aged; Mitochondria; Mitochondrial Proteins; Mitral Valve; Mitral Valve Insufficiency; Models, Anatomic; Molecular Structure; Molybdenum; Monocarboxylic Acid Transporters; Moths; MPTP Poisoning; Multigene Family; Multiparametric Magnetic Resonance Imaging; Multiple Myeloma; Muscle, Skeletal; Mutagens; Mutation; Myeloid Cells; Nanocomposites; Nanofibers; Nanomedicine; Nanoparticles; Nanowires; Neoadjuvant Therapy; Neomycin; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasms; Neoplastic Stem Cells; Neostriatum; Neovascularization, Pathologic; Netherlands; Neuromuscular Agents; Neurons; NF-E2-Related Factor 2; NF-kappa B; Nickel; Nitrogen Oxides; Non-alcoholic Fatty Liver Disease; Nucleosides; Nucleotidyltransferases; Nutritional Status; Obesity, Morbid; Ofloxacin; Oils, Volatile; Oligopeptides; Oncogene Protein v-akt; Optical Imaging; Organic Cation Transport Proteins; Organophosphonates; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Osteoblasts; Osteogenesis; Oxidation-Reduction; Oxidative Stress; Oxides; Oxygen Isotopes; Pancreas; Pancreaticoduodenectomy; Pandemics; Particle Size; Particulate Matter; Patient Acceptance of Health Care; Patient Compliance; PC-3 Cells; Peptide Fragments; Peptides; Periodontal Attachment Loss; Periodontal Index; Periodontal Pocket; Periodontitis; Peroxides; Peru; Pest Control, Biological; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Phylogeny; Pilot Projects; Piperidines; Plant Bark; Plant Extracts; Plant Leaves; Plasmids; Platelet Function Tests; Pneumonia, Viral; Podocytes; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Terephthalates; Polymers; Polymorphism, Single Nucleotide; Porosity; Portugal; Positron-Emission Tomography; Postoperative Complications; Postural Balance; Potassium Channels, Inwardly Rectifying; Povidone; Powders; Precancerous Conditions; Precision Medicine; Predictive Value of Tests; Pregnancy; Prenatal Care; Prognosis; Promoter Regions, Genetic; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Proteasome Inhibitors; Protective Agents; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Psychiatric Nursing; PTEN Phosphohydrolase; Pulmonary Embolism; Pyrimethamine; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reactive Oxygen Species; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, G-Protein-Coupled; Recombinational DNA Repair; Recovery of Function; Regional Blood Flow; Renal Dialysis; Renin; Renin-Angiotensin System; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Distress Syndrome; Retrospective Studies; Rhodamines; Risk Assessment; Risk Factors; RNA, Long Noncoding; RNA, Messenger; Running; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salinity; Salmeterol Xinafoate; Sarcoma; Seasons; Shoulder Injuries; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Sirtuins; Skull Fractures; Social Determinants of Health; Sodium; Sodium Fluoride; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Soil; Soil Pollutants; Spain; Spectrophotometry; Spectroscopy, Fourier Transform Infrared; Staphylococcal Protein A; Staphylococcus aureus; Stem Cells; Stereoisomerism; Stomach Neoplasms; Streptomyces; Strontium; Structure-Activity Relationship; Students, Nursing; Substance-Related Disorders; Succinic Acid; Sulfur; Surface Properties; Survival Rate; Survivin; Symporters; T-Lymphocytes; Temozolomide; Tensile Strength; Thiazoles; Thiobacillus; Thiohydantoins; Thiourea; Thrombectomy; Time Factors; Titanium; Tobacco Mosaic Virus; Tobacco Use Disorder; Toll-Like Receptor 4; Toluene; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Toxicity Tests, Acute; Toxicity Tests, Subacute; Transcriptional Activation; Treatment Outcome; Troponin I; Tumor Cells, Cultured; Tumor Escape; Tumor Hypoxia; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Tyrosine; Ubiquitin-Protein Ligases; Ubiquitination; Ultrasonic Waves; United Kingdom; United States; United States Department of Veterans Affairs; Up-Regulation; Urea; Uric Acid; Urinary Bladder Neoplasms; Urinary Bladder, Neurogenic; Urine; Urodynamics; User-Computer Interface; Vemurafenib; Verbenaceae; Veterans; Veterans Health; Viral Load; Virtual Reality; Vitiligo; Water Pollutants, Chemical; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Xylenes; Young Adult; Zinc; Zinc Oxide; Zinc Sulfate; Zoonoses

2021
Effects of Dapagliflozin on Cardiovascular Events, Death, and Safety Outcomes in Patients with Heart Failure: A Meta-Analysis.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2021, Volume: 21, Issue:3

    Topics: Benzhydryl Compounds; Blood Pressure; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Heart Failure; Humans; Randomized Controlled Trials as Topic; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors

2021
Highlights from Studies in Cardiovascular Disease Prevention Presented at the Digital 2020 European Society of Cardiology Congress: Prevention Is Alive and Well.
    Current atherosclerosis reports, 2020, 10-03, Volume: 22, Issue:12

    Topics: Benzhydryl Compounds; Betacoronavirus; Cardiology; Cardiovascular Agents; Cardiovascular Diseases; Clinical Trials as Topic; Congresses as Topic; Coronavirus Infections; COVID-19; Eicosapentaenoic Acid; Europe; Glucosides; Humans; Lipid Regulating Agents; Oligonucleotides; Pandemics; Pneumonia, Viral; SARS-CoV-2; Societies, Medical; Telecommunications

2020
Meta-analysis of Dedicated Renal Outcome Trials Assessing the Cardio-renal Efficacy of Sodium-Glucose Co-transporter-2 Inhibitors in Patients With Chronic Kidney Disease and Albuminuria.
    The American journal of cardiology, 2021, 01-01, Volume: 138

    Topics: Albuminuria; Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Hospitalization; Humans; Kidney Failure, Chronic; Renal Insufficiency, Chronic; Renal Replacement Therapy; Sodium-Glucose Transporter 2 Inhibitors

2021
TaleNeprilysin and Neprilysin inhibition in chronic kidney disease.
    Current opinion in nephrology and hypertension, 2021, Volume: 30, Issue:1

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzhydryl Compounds; Biphenyl Compounds; Cardiovascular Diseases; Chronic Disease; Disease Models, Animal; Disease Progression; Drug Combinations; Glucosides; Heart Failure; Humans; Mice; Natriuretic Peptides; Neprilysin; Renal Insufficiency, Chronic; Renin-Angiotensin System; Sodium-Glucose Transporter 2 Inhibitors; Valsartan

2021
SGLT2 inhibitors in people with and without T2DM.
    Nature reviews. Endocrinology, 2021, Volume: 17, Issue:2

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Disease Progression; Glucosides; Heart Failure; Hospitalization; Humans; Mortality; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors

2021
The Therapeutic Effects and Mechanisms of Salidroside on Cardiovascular and Metabolic Diseases: An Updated Review.
    Chemistry & biodiversity, 2021, Volume: 18, Issue:7

    Topics: Animals; Cardiovascular Diseases; Glucosides; Humans; Metabolic Diseases; Phenols

2021
Recent Insights Into the Protective Mechanisms of Paeoniflorin in Neurological, Cardiovascular, and Renal Diseases.
    Journal of cardiovascular pharmacology, 2021, 06-01, Volume: 77, Issue:6

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Drugs, Chinese Herbal; Glucosides; Humans; Kidney Diseases; Monoterpenes; Nervous System Diseases

2021
[Cardiovascular and renal protection of patients with type 2 diabetes : focus after EMPA-REG OUTCOME and LEADER].
    Revue medicale de Liege, 2016, Volume: 71, Issue:9

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Glucosides; Humans; Hypoglycemic Agents; Liraglutide; Risk Factors; Treatment Outcome

2016
Cardiovascular safety of liraglutide for the treatment of type 2 diabetes.
    Expert opinion on drug safety, 2017, Volume: 16, Issue:5

    Topics: Animals; Benzhydryl Compounds; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucagon-Like Peptide-1 Receptor; Glucosides; Humans; Hypoglycemic Agents; Liraglutide; Randomized Controlled Trials as Topic

2017
Mechanisms linking empagliflozin to cardiovascular and renal protection.
    International journal of cardiology, 2017, Aug-15, Volume: 241

    Topics: Benzhydryl Compounds; Cardiotonic Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Kidney Diseases; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors

2017
A consensus statement for the clinical use of the renal sodium-glucose co-transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes mellitus.
    Expert review of clinical pharmacology, 2017, Volume: 10, Issue:7

    Topics: Benzhydryl Compounds; Blood Glucose; Cardiovascular Diseases; Consensus; Delphi Technique; Diabetes Mellitus, Type 2; Glomerular Filtration Rate; Glucosides; Humans; Hypoglycemic Agents; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors

2017
Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms.
    The American journal of medicine, 2017, Volume: 130, Issue:6S

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Cardiomyopathies; Glucosides; Hemodynamics; Hormones; Humans; Hyperglycemia; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors

2017
Update on Cardiovascular Effects of Older and Newer Anti-diabetic Medications.
    Current medicinal chemistry, 2018, Volume: 25, Issue:13

    Topics: Benzhydryl Compounds; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptides; Glucosides; Humans; Hypoglycemic Agents; Insulin; Liraglutide; Metformin; Pioglitazone; Sodium-Glucose Transporter 2

2018
Interventions in type 2 diabetes mellitus and cardiovascular mortality-An overview of clinical trials.
    European journal of internal medicine, 2017, Volume: 42

    Topics: Benzhydryl Compounds; Blood Pressure; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Glucosides; Humans; Hypoglycemic Agents; Life Style; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Risk Factors

2017
Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms.
    The American journal of cardiology, 2017, 07-01, Volume: 120, Issue:1S

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Cardiomyopathies; Glucosides; Hemodynamics; Hormones; Humans; Hyperglycemia; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors

2017
EMPA-REG OUTCOME: The Endocrinologist's Point of View.
    The American journal of cardiology, 2017, 07-01, Volume: 120, Issue:1S

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Glucosides; Humans; Hypoglycemic Agents; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors

2017
EMPA-REG OUTCOME: The Cardiologist's Point of View.
    The American journal of cardiology, 2017, 07-01, Volume: 120, Issue:1S

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Cardiovascular Physiological Phenomena; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Glucosides; Hemodynamics; Humans; Hypoglycemic Agents; Myocardium; Oxygen Consumption; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Ventricular Function, Left

2017
Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials.
    Diabetes care, 2017, Volume: 40, Issue:7

    Topics: Animals; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptides; Glucosides; Humans; Hypoglycemic Agents; Liraglutide; Randomized Controlled Trials as Topic; Risk Factors; Treatment Outcome

2017
Durability of response to dapagliflozin: a review of long-term efficacy and safety.
    Current medical research and opinion, 2017, Volume: 33, Issue:9

    Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Renal Insufficiency; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome

2017
Benefits of SGLT2 Inhibitors Beyond Glycemic Control - A Focus on Metabolic, Cardiovascular and Renal Outcomes.
    Current diabetes reviews, 2018, Volume: 14, Issue:6

    Topics: Benzhydryl Compounds; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Kidney Diseases; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss

2018
The effect of SGLT2 inhibitors on cardiovascular events and renal function.
    Expert review of clinical pharmacology, 2017, Volume: 10, Issue:11

    Topics: Amputation, Surgical; Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Diabetic Nephropathies; Glucosides; Humans; Hypoglycemic Agents; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Stroke

2017
Clinical implications of current cardiovascular outcome trials with sodium glucose cotransporter-2 (SGLT2) inhibitors.
    Atherosclerosis, 2018, Volume: 272

    Topics: Albuminuria; Atherosclerosis; Benzhydryl Compounds; Body Weight; Canagliflozin; Cardiovascular Diseases; Cardiovascular System; Glucagon; Glucagon-Like Peptides; Glucosides; Heart Failure; Hemodynamics; Humans; Hypoglycemic Agents; Ketones; Lipids; Liraglutide; Metabolic Syndrome; Metformin; Non-alcoholic Fatty Liver Disease; Osmosis; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome

2018
Cardiovascular Mortality of Oral Antidiabetic Drugs Approved Before and After the 2008 US FDA Guidance for Industry: A Systemic Review and Meta-Analysis.
    Clinical drug investigation, 2018, Volume: 38, Issue:6

    Topics: Adult; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Randomized Controlled Trials as Topic; Risk; United States; United States Food and Drug Administration

2018
Renoprotective effects of sodium-glucose cotransporter-2 inhibitors.
    Kidney international, 2018, Volume: 94, Issue:1

    Topics: Benzhydryl Compounds; Blood Glucose; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Glucosides; Hospitalization; Humans; Kidney; Protective Agents; Renal Elimination; Sodium; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome

2018
Cardiovascular Benefit of SGLT2 Inhibitors in the Therapeutics of Diabetes Mellitus: A Close Look beyond the Horizon.
    Current drug targets, 2018, Volume: 19, Issue:9

    Topics: Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors

2018
Empagliflozin: A Review in Type 2 Diabetes.
    Drugs, 2018, Volume: 78, Issue:10

    Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Approval; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome

2018
Observational research on sodium glucose co-transporter-2 inhibitors: A real breakthrough?
    Diabetes, obesity & metabolism, 2018, Volume: 20, Issue:12

    Topics: Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Observational Studies as Topic; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome

2018
Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits.
    Diabetologia, 2018, Volume: 61, Issue:10

    Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Bone and Bones; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Glucosides; Humans; Hypoglycemic Agents; Ketosis; Kidney; Neoplasms; Randomized Controlled Trials as Topic; Risk Assessment; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss

2018
SGLT2 inhibitors: the future for treatment of type 2 diabetes mellitus and other chronic diseases.
    Diabetologia, 2018, Volume: 61, Issue:10

    Topics: Benzhydryl Compounds; Blood Glucose; Cardiovascular Diseases; Chronic Disease; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Non-alcoholic Fatty Liver Disease; Renal Insufficiency, Chronic; Risk; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors

2018
The role of glucagon in the possible mechanism of cardiovascular mortality reduction in type 2 diabetes patients.
    International journal of clinical practice, 2018, Volume: 72, Issue:12

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucagon; Glucosides; Humans; Hypoglycemic Agents; Insulin; Liraglutide

2018
Empagliflozin reduces blood pressure and uric acid in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.
    Journal of human hypertension, 2019, Volume: 33, Issue:4

    Topics: Adult; Aged; Benzhydryl Compounds; Biomarkers; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Lipids; Male; Middle Aged; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Uric Acid; Weight Loss

2019
Time-Matched Evaluation of Cardiovascular Risks Associated with Drugs for Type 2 Diabetes Mellitus.
    Clinical drug investigation, 2019, Volume: 39, Issue:5

    Topics: Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Follow-Up Studies; Glucagon-Like Peptides; Glucosides; Humans; Hypoglycemic Agents; Liraglutide; Risk Factors; Survival Rate

2019
Major Randomized Clinical Trials in Cardiovascular Disease Prevention Presented at the 2019 American College of Cardiology Annual Scientific Session.
    Current atherosclerosis reports, 2019, 05-24, Volume: 21, Issue:8

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antihypertensive Agents; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dicarboxylic Acids; Eicosapentaenoic Acid; Fatty Acids; Female; Glucosides; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; United States

2019
Dietary Flaxseed as a Strategy for Improving Human Health.
    Nutrients, 2019, May-25, Volume: 11, Issue:5

    Topics: alpha-Linolenic Acid; Animals; Anti-Inflammatory Agents; Antioxidants; Brain; Butylene Glycols; Cardiovascular Diseases; Diet; Dietary Fiber; Dietary Supplements; Fatty Acids, Omega-3; Female; Flax; Functional Food; Gastrointestinal Diseases; Glucosides; Hormones; Humans; Lignans; Lipid Metabolism; Neoplasms; Seeds

2019
An update on the safety and efficacy of oral antidiabetic drugs: DPP-4 inhibitors and SGLT-2 inhibitors.
    Expert opinion on drug safety, 2019, Volume: 18, Issue:8

    Topics: Administration, Oral; Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucosides; Humans; Hypoglycemic Agents; Patient Selection; Sodium-Glucose Transporter 2 Inhibitors

2019
Novel Antidiabetic Therapies and Cardiovascular Risk Reduction: The Role of the Noninferiority Trial.
    Cardiology clinics, 2019, Volume: 37, Issue:3

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Liraglutide; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors

2019
Class effects of SGLT2 inhibitors on cardiorenal outcomes.
    Cardiovascular diabetology, 2019, 08-05, Volume: 18, Issue:1

    Topics: Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Cardiovascular System; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Glucosides; Humans; Kidney; Protective Factors; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome

2019
Effects of dapagliflozin on cardiovascular risk factors.
    Postgraduate medicine, 2013, Volume: 125, Issue:3

    Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Risk Factors; Sodium-Glucose Transport Proteins

2013
Effect of the natural sweetener, steviol glycoside, on cardiovascular risk factors: a systematic review and meta-analysis of randomised clinical trials.
    European journal of preventive cardiology, 2015, Volume: 22, Issue:12

    Topics: Blood Glucose; Blood Pressure; Cardiovascular Diseases; Chi-Square Distribution; Diabetes Mellitus; Dietary Supplements; Diterpenes, Kaurane; Glucosides; Humans; Hypertension; Protective Factors; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Sweetening Agents

2015
POTENTIAL PLACE OF SGLT2 INHIBITORS IN TREATMENT PARADIGMS FOR TYPE 2 DIABETES MELLITUS.
    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2015, Volume: 21, Issue:9

    Topics: Aged; Aged, 80 and over; Aging; Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glomerular Filtration Rate; Glucosides; Humans; Hypoglycemic Agents; Kidney; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors

2015
SGLT2 inhibitors: new reports.
    The Medical letter on drugs and therapeutics, 2015, Oct-12, Volume: 57, Issue:1479

    Topics: Animals; Benzhydryl Compounds; Blood Glucose; Canagliflozin; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Research Report; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors

2015
A Safety Evaluation of Empagliflozin for the Treatment of Type 2 Diabetes.
    Expert opinion on drug safety, 2016, Volume: 15, Issue:3

    Topics: Adult; Animals; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2 Inhibitors

2016
Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis.
    Cardiovascular diabetology, 2016, Feb-19, Volume: 15

    Topics: Aged; Benzhydryl Compounds; Biomarkers; Blood Glucose; Cardiovascular Diseases; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Kaplan-Meier Estimate; Male; Middle Aged; Proportional Hazards Models; Protective Factors; Risk Assessment; Risk Factors; Sodium-Glucose Transport Proteins; Treatment Outcome

2016
Revitalization of pioglitazone: the optimum agent to be combined with a sodium-glucose co-transporter-2 inhibitor.
    Diabetes, obesity & metabolism, 2016, Volume: 18, Issue:5

    Topics: Animals; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Cardiomyopathies; Drug Therapy, Combination; Evidence-Based Medicine; Glucosides; Humans; Hypoglycemic Agents; Membrane Transport Modulators; Pioglitazone; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidinediones

2016
In Patients with Type 2 Diabetes and CV Disease, Empagliflozin Reduces CV and All-Cause Mortality.
    American family physician, 2016, Mar-01, Volume: 93, Issue:5

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Global Health; Glucosides; Humans; Hypoglycemic Agents; Survival Rate

2016
Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis.
    The lancet. Diabetes & endocrinology, 2016, Volume: 4, Issue:5

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Risk Assessment; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors

2016
Cardiovascular outcomes of sodium-glucose cotransporter 2 inhibitors: A comprehensive review of clinical and preclinical studies.
    International journal of cardiology, 2016, Jun-01, Volume: 212

    Topics: Animals; Benzhydryl Compounds; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Evaluation, Preclinical; Glucosides; Humans; Hypoglycemic Agents; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome

2016
SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?
    Diabetologia, 2016, Volume: 59, Issue:7

    Topics: Animals; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Kidney; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors

2016
The cardiovascular phenotype: impact on choice of glucose- lowering therapy.
    JPMA. The Journal of the Pakistan Medical Association, 2016, Volume: 66, Issue:4

    Topics: Acarbose; Benzhydryl Compounds; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dyslipidemias; Glucosides; Heart Rate; Humans; Hypoglycemic Agents; Metformin; Obesity; Phenotype

2016
[Novel therapeutic options in patients with type 2 diabetes and high cardiovascular risk].
    Deutsche medizinische Wochenschrift (1946), 2016, Volume: 141, Issue:11

    Topics: Administration, Oral; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Survival Rate; Treatment Outcome; Weight Loss

2016
The EMPA-REG outcome study: critical appraisal and potential clinical implications.
    Cardiovascular diabetology, 2016, Jun-04, Volume: 15

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Outcome Assessment, Health Care; Risk Factors

2016
Reappraisal of the diuretic effect of empagliflozin in the EMPA-REG OUTCOME trial: Comparison with classic diuretics.
    Diabetes & metabolism, 2016, Volume: 42, Issue:4

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diuretics; Glucosides; Humans; Hypertension; Hypoglycemic Agents; Treatment Outcome

2016
Novel antidiabetic drugs and cardiovascular risk: Primum non nocere.
    Nutrition, metabolism, and cardiovascular diseases : NMCD, 2016, Volume: 26, Issue:9

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucosides; Humans; Hypoglycemic Agents; Incretins; Patient Safety; Patient Selection; Risk Assessment; Risk Factors; Sitagliptin Phosphate; Treatment Outcome

2016
Cardiovascular safety of empagliflozin in patients with type 2 diabetes: a meta-analysis of data from randomized placebo-controlled trials.
    Diabetes, obesity & metabolism, 2016, Volume: 18, Issue:10

    Topics: Aged; Benzhydryl Compounds; Cardiotoxicity; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Placebos; Randomized Controlled Trials as Topic; Risk Factors

2016
Research digest.
    The lancet. Diabetes & endocrinology, 2016, Volume: 4, Issue:8

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus; Glomerular Filtration Rate; Glucosides; Humans; Hypoglycemic Agents; Liraglutide

2016
Empagliflozin (Jardiance). Type 2 diabetes: no rush to use this drug.
    Prescrire international, 2016, Volume: 25, Issue:172

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents

2016
Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials.
    Acta diabetologica, 2017, Volume: 54, Issue:1

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes

2017
New Oral Hypoglycemic Agents and Cardiovascular Risk. Crossing the Metabolic Border.
    Revista espanola de cardiologia (English ed.), 2016, Volume: 69, Issue:11

    Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Proteinuria; Risk; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Uric Acid; Vascular Stiffness

2016
Impact of EMPA-REG OUTCOME
    Postgraduate medicine, 2016, Volume: 128, Issue:8

    Topics: Benzhydryl Compounds; Body Weights and Measures; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Primary Health Care; Randomized Controlled Trials as Topic; Renal Insufficiency; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors

2016
Effects of reducing blood pressure on cardiovascular outcomes and mortality in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME.
    Diabetes research and clinical practice, 2016, Volume: 121

    Topics: Benzhydryl Compounds; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors

2016
Which is the main molecular target responsible for the cardiovascular benefits in the EMPA-REG OUTCOME trial? A journey through the kidney, the heart and other interesting places.
    Nutrition, metabolism, and cardiovascular diseases : NMCD, 2016, Volume: 26, Issue:12

    Topics: Animals; Benzhydryl Compounds; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucosides; Heart; Humans; Hypoglycemic Agents; Kidney; Myocytes, Cardiac; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome

2016
Implications of the EMPA-REG Trial for Clinical Care and Research.
    Current diabetes reports, 2016, Volume: 16, Issue:12

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Kidney Diseases; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors

2016
Stroke paradox with SGLT-2 inhibitors: a play of chance or a viscosity-mediated reality?
    Journal of neurology, neurosurgery, and psychiatry, 2017, Volume: 88, Issue:3

    Topics: Benzhydryl Compounds; Blood Viscosity; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Risk Factors; Stroke

2017
Emerging roles of sodium-glucose cotransporter 2 inhibitors in cardiology.
    Journal of cardiology, 2017, Volume: 69, Issue:3

    Topics: Benzhydryl Compounds; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 1

2017
Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Nonglycemic Outcomes in Patients with Type 2 Diabetes.
    Pharmacotherapy, 2017, Volume: 37, Issue:4

    Topics: Benzhydryl Compounds; Blood Glucose; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors

2017
Blood pressure reduction in diabetes: lessons from ACCORD, SPRINT and EMPA-REG OUTCOME.
    Nature reviews. Endocrinology, 2017, Volume: 13, Issue:6

    Topics: Antihypertensive Agents; Benzhydryl Compounds; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypertension; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Reference Values; Treatment Outcome

2017
SGLT2 Inhibition in the Diabetic Kidney-From Mechanisms to Clinical Outcome.
    Clinical journal of the American Society of Nephrology : CJASN, 2017, Apr-03, Volume: 12, Issue:4

    Topics: Albuminuria; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucose; Glucosides; Humans; Hypoglycemic Agents; Lipid Metabolism; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss

2017
Integrated cardiovascular safety: multifaceted considerations in drug development and therapeutic use.
    Expert opinion on drug safety, 2017, Volume: 16, Issue:4

    Topics: Adult; Animals; Antineoplastic Agents; Benzhydryl Compounds; Blood Pressure; Cardiotoxicity; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Design; Glucosides; Humans; Hypoglycemic Agents

2017
Dapagliflozin: potential beneficial effects in the prevention and treatment of renal and cardiovascular complications in patients with type 2 diabetes.
    Expert opinion on pharmacotherapy, 2017, Volume: 18, Issue:5

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucosides; Humans; Hyperglycemia; Hypoglycemic Agents; Kidney Failure, Chronic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors

2017
Health effects with consumption of the flax lignan secoisolariciresinol diglucoside.
    The British journal of nutrition, 2010, Volume: 103, Issue:7

    Topics: Animals; Antioxidants; Butylene Glycols; Cardiovascular Diseases; Diabetes Mellitus; Diet; Enzyme Activators; Enzyme Inhibitors; Female; Flax; Glucosides; Humans; Lignin; Neoplasms; Phytoestrogens; Pregnancy

2010
Aspirin: a history, a love story.
    The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists, 2012, Volume: 27, Issue:5

    Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Benzyl Alcohols; Cardiovascular Diseases; Drug Hypersensitivity; Drug Resistance; Glucosides; History, 18th Century; History, 19th Century; History, 20th Century; Humans; Neoplasms; Salix; Sex Characteristics

2012

Trials

83 trial(s) available for glucose, (beta-d)-isomer and Cardiovascular Diseases

ArticleYear
Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the EMPA-REG OUTCOME trial.
    Diabetes, obesity & metabolism, 2021, Volume: 23, Issue:12

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Insulin; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome

2021
Empagliflozin and uric acid metabolism in diabetes: A post hoc analysis of the EMPA-REG OUTCOME trial.
    Diabetes, obesity & metabolism, 2022, Volume: 24, Issue:1

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Treatment Outcome; Uric Acid

2022
Cost-Effectiveness of Empagliflozin in Patients With Diabetic Kidney Disease in the United States: Findings Based on the EMPA-REG OUTCOME Trial.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2022, Volume: 79, Issue:6

    Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucose; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Medicare; Myocardial Infarction; United States

2022
The effect of empagliflozin on the total burden of cardiovascular and hospitalization events in the Asian and non-Asian populations of the EMPA-REG OUTCOME trial of patients with type 2 diabetes and cardiovascular disease.
    Diabetes, obesity & metabolism, 2022, Volume: 24, Issue:4

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Hospitalization; Humans; Hypoglycemic Agents; Treatment Outcome

2022
Randomized Controlled Trial of the Hemodynamic Effects of Empagliflozin in Patients With Type 2 Diabetes at High Cardiovascular Risk: The SIMPLE Trial.
    Diabetes, 2022, 04-01, Volume: 71, Issue:4

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Heart Disease Risk Factors; Hemodynamics; Humans; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome

2022
Effect of empagliflozin on coronary microvascular function in patients with type 2 diabetes mellitus-A randomized, placebo-controlled cross-over study.
    PloS one, 2022, Volume: 17, Issue:2

    Topics: Adult; Aged; Benzhydryl Compounds; Biomarkers; Blood Flow Velocity; Cardiovascular Diseases; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Echocardiography; Echocardiography, Doppler; Female; Glucosides; Humans; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors

2022
Effects of empagliflozin on markers of liver steatosis and fibrosis and their relationship to cardiorenal outcomes.
    Diabetes, obesity & metabolism, 2022, Volume: 24, Issue:6

    Topics: Benzhydryl Compounds; Biomarkers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Fibrosis; Glucosides; Humans; Non-alcoholic Fatty Liver Disease; Treatment Outcome

2022
Empagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition?
    The Journal of clinical endocrinology and metabolism, 2022, 06-16, Volume: 107, Issue:7

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Nephrolithiasis; Prospective Studies; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Urinary Calculi

2022
Cardiovascular Benefits of Empagliflozin Are Associated With Gut Microbiota and Plasma Metabolites in Type 2 Diabetes.
    The Journal of clinical endocrinology and metabolism, 2022, 06-16, Volume: 107, Issue:7

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Gastrointestinal Microbiome; Glucose; Glucosides; Humans; Hypoglycemic Agents; RNA, Ribosomal, 16S

2022
Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial.
    Diabetologia, 2022, Volume: 65, Issue:7

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glomerular Filtration Rate; Glucosides; Heart Failure; Humans; Kidney; Kidney Failure, Chronic; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors

2022
Evolocumab on top of empagliflozin improves endothelial function of individuals with diabetes: randomized active-controlled trial.
    Cardiovascular diabetology, 2022, 08-06, Volume: 21, Issue:1

    Topics: Antibodies, Monoclonal, Humanized; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Isoprostanes; Male; Middle Aged; PCSK9 Inhibitors; Proprotein Convertase 9; Treatment Outcome

2022
Investigating the roles of hyperglycaemia, hyperinsulinaemia and elevated free fatty acids in cardiac function in patients with type 2 diabetes via treatment with insulin compared with empagliflozin: protocol for the HyperCarD2 randomised, crossover trial
    BMJ open, 2022, 08-11, Volume: 12, Issue:8

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Cross-Over Studies; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Glucose; Glucosides; Humans; Hyperglycemia; Hyperinsulinism; Hypoglycemic Agents; Insulin; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Ventricular Function, Left

2022
Effects of the SGLT2 inhibitor dapagliflozin on cardiac function evaluated by impedance cardiography in patients with type 2 diabetes. Secondary analysis of a randomized placebo-controlled trial.
    Cardiovascular diabetology, 2019, 08-14, Volume: 18, Issue:1

    Topics: Aged; Benzhydryl Compounds; Biomarkers; Blood Glucose; Cardiography, Impedance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Heart; Hemodynamics; Humans; Italy; Male; Middle Aged; Predictive Value of Tests; Single-Blind Method; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome

2019
SGLT2 Inhibition with Empagliflozin Increases Circulating Provascular Progenitor Cells in People with Type 2 Diabetes Mellitus.
    Cell metabolism, 2019, 10-01, Volume: 30, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Cardiotonic Agents; Cardiovascular Diseases; Coronary Artery Disease; Diabetes Mellitus, Type 2; Glucosides; Humans; Middle Aged; Myeloid Progenitor Cells; Regeneration; Sodium-Glucose Transporter 2 Inhibitors

2019
Relationship between hypoglycaemia, cardiovascular outcomes, and empagliflozin treatment in the EMPA-REG OUTCOME® trial.
    European heart journal, 2020, 01-07, Volume: 41, Issue:2

    Topics: Benzhydryl Compounds; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Male; Middle Aged; Prognosis; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Time Factors

2020
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
    The New England journal of medicine, 2019, 11-21, Volume: 381, Issue:21

    Topics: Aged; Benzhydryl Compounds; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Heart Failure; Hospitalization; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Ventricular Dysfunction, Left

2019
Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME® trial.
    Age and ageing, 2019, 11-01, Volume: 48, Issue:6

    Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Myocardial Infarction; Stroke

2019
Design of a randomised controlled trial of the effects of empagliflozin on myocardial perfusion, function and metabolism in type 2 diabetes patients at high cardiovascular risk (the SIMPLE trial).
    BMJ open, 2019, 11-27, Volume: 9, Issue:11

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Denmark; Diabetes Mellitus, Type 2; Double-Blind Method; Glucosides; Humans; Randomized Controlled Trials as Topic; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome

2019
Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose-lowering therapy?
    Diabetes, obesity & metabolism, 2020, Volume: 22, Issue:4

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucose; Glucosides; Humans; Hypoglycemic Agents; Kidney

2020
Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR).
    Cardiovascular diabetology, 2020, 01-07, Volume: 19, Issue:1

    Topics: Aged; Benzhydryl Compounds; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucosides; Glycated Hemoglobin; Humans; Japan; Male; Metabolic Syndrome; Middle Aged; Prospective Studies; Risk Assessment; Risk Factors; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome; Weight Loss

2020
Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2020, 02-01, Volume: 35, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Glomerular Filtration Rate; Glucosides; Humans; Male; Middle Aged; Prognosis; Renal Insufficiency, Chronic; Research Design; Sodium-Glucose Transporter 2 Inhibitors; Young Adult

2020
Can the cardiovascular risk reductions observed with empagliflozin in the EMPA-REG OUTCOME trial be explained by concomitant changes seen in conventional cardiovascular risk factor levels?
    Diabetes, obesity & metabolism, 2020, Volume: 22, Issue:7

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Heart Disease Risk Factors; Humans; Hypoglycemic Agents; Risk Factors

2020
Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes.
    JAMA, 2020, 04-14, Volume: 323, Issue:14

    Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Heart Failure; Humans; Hypoglycemic Agents; Male; Middle Aged; Placebos; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Ventricular Dysfunction, Left

2020
Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPA-REG OUTCOME trial.
    Diabetes, obesity & metabolism, 2020, Volume: 22, Issue:7

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Hospitalization; Humans; Myocardial Infarction; Risk Factors; Thrombolytic Therapy

2020
Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial.
    The Journal of clinical endocrinology and metabolism, 2020, 09-01, Volume: 105, Issue:9

    Topics: Aged; Benzhydryl Compounds; Blood Glucose; Cardiotonic Agents; Cardiovascular Diseases; Cardiovascular System; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Heart Disease Risk Factors; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Retrospective Studies; Risk Assessment; Risk Factors; Treatment Outcome

2020
Secondary analyses to assess the profound effects of empagliflozin on endothelial function in patients with type 2 diabetes and established cardiovascular diseases: The placebo-controlled double-blind randomized effect of empagliflozin on endothelial func
    Journal of diabetes investigation, 2020, Volume: 11, Issue:6

    Topics: Aged; Benzhydryl Compounds; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Endothelium, Vascular; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; Male; Middle Aged; Prognosis; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors

2020
Cardiorenal outcomes with dapagliflozin by baseline glucose-lowering agents: Post hoc analyses from DECLARE-TIMI 58.
    Diabetes, obesity & metabolism, 2021, Volume: 23, Issue:1

    Topics: Benzhydryl Compounds; Brain Ischemia; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucose; Glucosides; Humans; Hypoglycemic Agents; Stroke; Treatment Outcome

2021
The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2020, 10-01, Volume: 35, Issue:10

    Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Glomerular Filtration Rate; Glucosides; Humans; Male; Prognosis; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors

2020
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acrylic Resins; Actinobacillus; Acute Disease; Acute Kidney Injury; Adaptor Proteins, Signal Transducing; Adenosine; Adenosine Triphosphate; Administration, Inhalation; Administration, Oral; Adolescent; Adult; Advance Care Planning; Africa, Northern; Age Factors; Aged; Aged, 80 and over; Air Pollutants; Air Pollution; Air Pollution, Indoor; Albendazole; Aluminum Oxide; Anastomosis, Surgical; Ancylostoma; Ancylostomiasis; Androstadienes; Angiogenesis Inhibitors; Angiotensin II; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bispecific; Antibodies, Viral; Anticoagulants; Antihypertensive Agents; Antinematodal Agents; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antiporters; Antiviral Agents; Apoptosis; Aptamers, Nucleotide; Aromatase Inhibitors; Asian People; Astrocytes; Atrial Fibrillation; Auditory Threshold; Aurora Kinase B; Australia; Autophagy; Autophagy-Related Protein 5; Autotrophic Processes; Bacillus cereus; Bacillus thuringiensis; Bacterial Proteins; Beclin-1; Belgium; Benzene; Benzene Derivatives; Benzhydryl Compounds; beta Catenin; beta-Arrestin 2; Biliary Tract Diseases; Biofilms; Biofuels; Biomarkers; Biomarkers, Tumor; Biomass; Biomechanical Phenomena; Bioreactors; Biosensing Techniques; Biosynthetic Pathways; Bismuth; Blood Platelets; Bone and Bones; Bone Regeneration; Bortezomib; Botulinum Toxins, Type A; Brain; Brain Injuries; Brain Ischemia; Brain Neoplasms; Breast Neoplasms; Breath Tests; Bronchodilator Agents; Calcium Phosphates; Cannabis; Carbon Dioxide; Carbon Isotopes; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cardiac Resynchronization Therapy; Cardiac Resynchronization Therapy Devices; Cardiomyopathies; Cardiovascular Diseases; Cariostatic Agents; Case Managers; Case-Control Studies; Catalysis; Cation Transport Proteins; CD8-Positive T-Lymphocytes; Cecropia Plant; Cell Adhesion; Cell Count; Cell Differentiation; Cell Division; Cell Line; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Self Renewal; Cell Survival; Cells, Cultured; Cellular Reprogramming; Cellulose; Charcoal; Chemical and Drug Induced Liver Injury; Chemical Phenomena; Chemokines; Chemoradiotherapy; Chemoreceptor Cells; Child; Child Abuse; Child, Preschool; China; Chlorogenic Acid; Chloroquine; Chromatography, Gas; Chronic Disease; Clinical Competence; Coated Materials, Biocompatible; Cochlea; Cohort Studies; Color; Comorbidity; Computer Simulation; Computer-Aided Design; Contraception; Contraceptive Agents, Female; Contrast Media; COP-Coated Vesicles; Coronavirus Infections; Cost of Illness; Coturnix; COVID-19; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Culex; Curriculum; Cyclic N-Oxides; Cytokines; Cytoplasm; Cytotoxicity, Immunologic; Cytotoxins; Databases, Factual; Deep Learning; Delivery, Obstetric; Denitrification; Dental Caries; Denture, Complete; Dexamethasone; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dielectric Spectroscopy; Diet, High-Fat; Dietary Fiber; Disease Models, Animal; Disease Progression; DNA; DNA Copy Number Variations; DNA, Mitochondrial; Dog Diseases; Dogs; Dopaminergic Neurons; Double-Blind Method; Down-Regulation; Doxorubicin; Drug Carriers; Drug Design; Drug Interactions; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Drugs, Chinese Herbal; Dry Powder Inhalers; Dust; E2F1 Transcription Factor; Ecosystem; Education, Nursing; Education, Nursing, Baccalaureate; Electric Impedance; Electricity; Electrocardiography; Electrochemical Techniques; Electrochemistry; Electrodes; Electrophoresis, Polyacrylamide Gel; Endoplasmic Reticulum; Endothelial Cells; Environmental Monitoring; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Estrogen Receptor Modulators; Europe; Evoked Potentials, Auditory, Brain Stem; Exosomes; Feasibility Studies; Female; Ferricyanides; Ferrocyanides; Fibrinogen; Finite Element Analysis; Fistula; Fluorescent Dyes; Fluorides, Topical; Fluorodeoxyglucose F18; Fluticasone; Follow-Up Studies; Food Contamination; Food Microbiology; Foods, Specialized; Forensic Medicine; Frail Elderly; France; Free Radicals; Fresh Water; Fungi; Fungicides, Industrial; Galactosamine; Gastrointestinal Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Frequency; Genetic Predisposition to Disease; Genotype; Gingival Hemorrhage; Glioblastoma; Glioma; Glomerular Filtration Rate; Glomerulosclerosis, Focal Segmental; Glucose; Glucose Transport Proteins, Facilitative; Glucosides; Glutamine; Glycolysis; Gold; GPI-Linked Proteins; Gram-Negative Bacteria; Gram-Positive Bacteria; Graphite; Haplotypes; HCT116 Cells; Healthy Volunteers; Hearing Loss; Heart Failure; Hedgehog Proteins; HEK293 Cells; HeLa Cells; Hemodynamics; Hemorrhage; Hepatocytes; Hippo Signaling Pathway; Histone Deacetylases; Homeostasis; Hospital Mortality; Hospitalization; Humans; Hydantoins; Hydrazines; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Hydroxylamines; Hypoglycemic Agents; Immunity, Innate; Immunoglobulin G; Immunohistochemistry; Immunologic Factors; Immunomodulation; Immunophenotyping; Immunotherapy; Incidence; Indazoles; Indonesia; Infant; Infant, Newborn; Infarction, Middle Cerebral Artery; Inflammation; Injections, Intramuscular; Insecticides; Insulin-Like Growth Factor I; Insurance, Health; Intention to Treat Analysis; Interleukin-1 Receptor-Associated Kinases; Interleukin-6; Intrauterine Devices; Intrauterine Devices, Copper; Iron; Ischemia; Jordan; Keratinocytes; Kidney; Kidney Diseases; Kir5.1 Channel; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Laparoscopy; Lasers; Lasers, Semiconductor; Lenalidomide; Leptin; Lethal Dose 50; Levonorgestrel; Limit of Detection; Lipid Metabolism; Lipid Metabolism Disorders; Lipogenesis; Lipopolysaccharides; Liquid Biopsy; Liver; Liver Abscess, Pyogenic; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Longevity; Lung Neoplasms; Luteolin; Lymph Nodes; Lymphocyte Activation; Macaca fascicularis; Macrophages; Mad2 Proteins; Magnetic Resonance Imaging; Male; Mammary Glands, Human; Manganese; Manganese Compounds; MAP Kinase Signaling System; Materials Testing; Maternal Health Services; MCF-7 Cells; Medicaid; Medicine, Chinese Traditional; Melanoma; Membrane Proteins; Mental Health; Mercury; Metal Nanoparticles; Metals, Heavy; Metformin; Methionine Adenosyltransferase; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Knockout; Mice, Nude; Microalgae; Microbial Sensitivity Tests; Microglia; MicroRNAs; Microscopy, Atomic Force; Microscopy, Electron, Scanning; Middle Aged; Mitochondria; Mitochondrial Proteins; Mitral Valve; Mitral Valve Insufficiency; Models, Anatomic; Molecular Structure; Molybdenum; Monocarboxylic Acid Transporters; Moths; MPTP Poisoning; Multigene Family; Multiparametric Magnetic Resonance Imaging; Multiple Myeloma; Muscle, Skeletal; Mutagens; Mutation; Myeloid Cells; Nanocomposites; Nanofibers; Nanomedicine; Nanoparticles; Nanowires; Neoadjuvant Therapy; Neomycin; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasms; Neoplastic Stem Cells; Neostriatum; Neovascularization, Pathologic; Netherlands; Neuromuscular Agents; Neurons; NF-E2-Related Factor 2; NF-kappa B; Nickel; Nitrogen Oxides; Non-alcoholic Fatty Liver Disease; Nucleosides; Nucleotidyltransferases; Nutritional Status; Obesity, Morbid; Ofloxacin; Oils, Volatile; Oligopeptides; Oncogene Protein v-akt; Optical Imaging; Organic Cation Transport Proteins; Organophosphonates; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Osteoblasts; Osteogenesis; Oxidation-Reduction; Oxidative Stress; Oxides; Oxygen Isotopes; Pancreas; Pancreaticoduodenectomy; Pandemics; Particle Size; Particulate Matter; Patient Acceptance of Health Care; Patient Compliance; PC-3 Cells; Peptide Fragments; Peptides; Periodontal Attachment Loss; Periodontal Index; Periodontal Pocket; Periodontitis; Peroxides; Peru; Pest Control, Biological; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Phylogeny; Pilot Projects; Piperidines; Plant Bark; Plant Extracts; Plant Leaves; Plasmids; Platelet Function Tests; Pneumonia, Viral; Podocytes; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Terephthalates; Polymers; Polymorphism, Single Nucleotide; Porosity; Portugal; Positron-Emission Tomography; Postoperative Complications; Postural Balance; Potassium Channels, Inwardly Rectifying; Povidone; Powders; Precancerous Conditions; Precision Medicine; Predictive Value of Tests; Pregnancy; Prenatal Care; Prognosis; Promoter Regions, Genetic; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Proteasome Inhibitors; Protective Agents; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Psychiatric Nursing; PTEN Phosphohydrolase; Pulmonary Embolism; Pyrimethamine; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reactive Oxygen Species; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, G-Protein-Coupled; Recombinational DNA Repair; Recovery of Function; Regional Blood Flow; Renal Dialysis; Renin; Renin-Angiotensin System; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Distress Syndrome; Retrospective Studies; Rhodamines; Risk Assessment; Risk Factors; RNA, Long Noncoding; RNA, Messenger; Running; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salinity; Salmeterol Xinafoate; Sarcoma; Seasons; Shoulder Injuries; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Sirtuins; Skull Fractures; Social Determinants of Health; Sodium; Sodium Fluoride; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Soil; Soil Pollutants; Spain; Spectrophotometry; Spectroscopy, Fourier Transform Infrared; Staphylococcal Protein A; Staphylococcus aureus; Stem Cells; Stereoisomerism; Stomach Neoplasms; Streptomyces; Strontium; Structure-Activity Relationship; Students, Nursing; Substance-Related Disorders; Succinic Acid; Sulfur; Surface Properties; Survival Rate; Survivin; Symporters; T-Lymphocytes; Temozolomide; Tensile Strength; Thiazoles; Thiobacillus; Thiohydantoins; Thiourea; Thrombectomy; Time Factors; Titanium; Tobacco Mosaic Virus; Tobacco Use Disorder; Toll-Like Receptor 4; Toluene; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Toxicity Tests, Acute; Toxicity Tests, Subacute; Transcriptional Activation; Treatment Outcome; Troponin I; Tumor Cells, Cultured; Tumor Escape; Tumor Hypoxia; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Tyrosine; Ubiquitin-Protein Ligases; Ubiquitination; Ultrasonic Waves; United Kingdom; United States; United States Department of Veterans Affairs; Up-Regulation; Urea; Uric Acid; Urinary Bladder Neoplasms; Urinary Bladder, Neurogenic; Urine; Urodynamics; User-Computer Interface; Vemurafenib; Verbenaceae; Veterans; Veterans Health; Viral Load; Virtual Reality; Vitiligo; Water Pollutants, Chemical; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Xylenes; Young Adult; Zinc; Zinc Oxide; Zinc Sulfate; Zoonoses

2021
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
    The New England journal of medicine, 2020, 10-08, Volume: 383, Issue:15

    Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Disease Progression; Double-Blind Method; Female; Glomerular Filtration Rate; Glucosides; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Proportional Hazards Models; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume

2020
Dapagliflozin in Patients with Chronic Kidney Disease.
    The New England journal of medicine, 2020, 10-08, Volume: 383, Issue:15

    Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glomerular Filtration Rate; Glucosides; Humans; Kaplan-Meier Estimate; Kidney Failure, Chronic; Male; Middle Aged; Regression Analysis; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors

2020
Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories:
    Clinical journal of the American Society of Nephrology : CJASN, 2020, 10-07, Volume: 15, Issue:10

    Topics: Adams-Stokes Syndrome; Aged; Albuminuria; Benzhydryl Compounds; Cardiovascular Diseases; Creatinine; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Genital Diseases, Female; Genital Diseases, Male; Glomerular Filtration Rate; Glucosides; Heart Failure; Hospitalization; Humans; Infections; Male; Middle Aged; Mortality; Myocardial Infarction; Placebos; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors

2020
The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial.
    Diabetes care, 2020, Volume: 43, Issue:12

    Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Cardiovascular System; Comorbidity; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glucosides; Humans; Incidence; Kidney Diseases; Male; Middle Aged; Prevalence; Risk Factors; Sleep; Sleep Apnea, Obstructive; Treatment Outcome

2020
Effects of dapagliflozin on cardiovascular outcomes in type 2 diabetes: Study protocol of a randomized controlled trial.
    Medicine, 2020, Oct-09, Volume: 99, Issue:41

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Glucosides; Humans; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors

2020
Empagliflozin reduced long-term HbA1c variability and cardiovascular death: insights from the EMPA-REG OUTCOME trial.
    Cardiovascular diabetology, 2020, 10-13, Volume: 19, Issue:1

    Topics: Benzhydryl Compounds; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Glycemic Control; Humans; Male; Middle Aged; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome

2020
Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease.
    Circulation, 2021, 02-02, Volume: 143, Issue:5

    Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Double-Blind Method; Female; Glucosides; Humans; Male; Middle Aged; Renal Insufficiency, Chronic

2021
Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID-19: Design and rationale for the DARE-19 study.
    Diabetes, obesity & metabolism, 2021, Volume: 23, Issue:4

    Topics: Atherosclerosis; Benzhydryl Compounds; Cardiometabolic Risk Factors; Cardiovascular Diseases; Cause of Death; Comorbidity; COVID-19; COVID-19 Drug Treatment; Diabetes Mellitus, Type 2; Disease Progression; Double-Blind Method; Glucosides; Heart Failure; Humans; Hypertension; Kidney Diseases; Mortality; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Respiratory Insufficiency; SARS-CoV-2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome

2021
Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial.
    The lancet. Diabetes & endocrinology, 2021, Volume: 9, Issue:1

    Topics: Adult; Aged; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Glucosides; Heart Failure; Humans; Kidney; Kidney Failure, Chronic; Male; Middle Aged; Renal Insufficiency, Chronic; Treatment Outcome

2021
Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized controlled study.
    Cardiovascular diabetology, 2021, 01-07, Volume: 20, Issue:1

    Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Germany; Glucosides; Heart Failure; Humans; Male; Middle Aged; Patient Admission; Pilot Projects; Prospective Studies; Recovery of Function; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Time Factors; Treatment Outcome; Vascular Resistance; Ventricular Function, Left; Ventricular Pressure

2021
A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the ASSET study.
    Cardiovascular diabetology, 2021, 02-02, Volume: 20, Issue:1

    Topics: Adiposity; Adult; Benzhydryl Compounds; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Energy Metabolism; Female; Glucosides; Glycated Hemoglobin; Heart; Humans; Male; Middle Aged; Myocardium; Primary Prevention; Prospective Studies; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Tokyo; Treatment Outcome

2021
Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction.
    JAMA cardiology, 2021, 05-01, Volume: 6, Issue:5

    Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Disease Progression; Double-Blind Method; Female; Glucosides; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Numbers Needed To Treat; Proportional Hazards Models; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Time Factors; Ventricular Dysfunction, Left

2021
Cardio/Kidney Composite End Points: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial.
    Journal of the American Heart Association, 2021, 04-06, Volume: 10, Issue:7

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glomerular Filtration Rate; Glucosides; Humans; Hypoglycemic Agents; Kidney; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors

2021
Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial.
    European heart journal, 2021, 03-31, Volume: 42, Issue:13

    Topics: Adult; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Rate; Glucosides; Humans; Male; Middle Aged; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors

2021
Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
    JAMA cardiology, 2021, 07-01, Volume: 6, Issue:7

    Topics: Aged; Albuminuria; Benzhydryl Compounds; Cardiovascular Diseases; Creatinine; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Rate; Glucosides; Heart Failure; Humans; Male; Middle Aged; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome

2021
Dapagliflozin and measures of cardiovascular autonomic function in patients with type 2 diabetes (T2D).
    Journal of diabetes and its complications, 2021, Volume: 35, Issue:8

    Topics: Aged; Benzhydryl Compounds; Blood Glucose; Cardiovascular Diseases; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Middle Aged; Prospective Studies; Treatment Outcome

2021
Reduction of estimated fluid volumes following initiation of empagliflozin in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the placebo-controlled, randomized EMBLEM trial.
    Cardiovascular diabetology, 2021, 06-28, Volume: 20, Issue:1

    Topics: Aged; Benzhydryl Compounds; Biomarkers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fluid Shifts; Glucosides; Humans; Japan; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Plasma Volume; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome; Water-Electrolyte Balance

2021
Comparison of the clinical effect of empagliflozin on glycemic and non-glycemic parameters in Japanese patients with type 2 diabetes and cardiovascular disease treated with or without baseline metformin.
    Cardiovascular diabetology, 2021, 07-31, Volume: 20, Issue:1

    Topics: Aged; Benzhydryl Compounds; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Glycemic Control; Humans; Japan; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome

2021
Empagliflozin in Heart Failure with a Preserved Ejection Fraction.
    The New England journal of medicine, 2021, 10-14, Volume: 385, Issue:16

    Topics: Adult; Benzhydryl Compounds; Cardiovascular Diseases; Chronic Disease; Double-Blind Method; Female; Glucosides; Heart Failure; Hospitalization; Humans; Male; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume

2021
Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year.
    Diabetes, obesity & metabolism, 2017, Volume: 19, Issue:9

    Topics: Adiposity; Anti-Obesity Agents; Benzhydryl Compounds; Body Mass Index; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Exenatide; Female; Follow-Up Studies; Ghrelin; Glucosides; Humans; Hypoglycemic Agents; Male; Membrane Transport Modulators; Middle Aged; Obesity; Peptides; Prediabetic State; Proof of Concept Study; Risk Factors; Sodium-Glucose Transport Proteins; Sweden; Venoms; Weight Loss

2017
Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk.
    Stroke, 2017, Volume: 48, Issue:5

    Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Outcome Assessment, Health Care; Risk; Stroke

2017
Protocol for a randomised controlled trial of the effect of dapagliflozin, metformin and exercise on glycaemic variability, body composition and cardiovascular risk in prediabetes (the PRE-D Trial).
    BMJ open, 2017, 06-06, Volume: 7, Issue:5

    Topics: Adult; Aged; Benzhydryl Compounds; Body Composition; Body Weight; Cardiovascular Diseases; Denmark; Double-Blind Method; Exercise; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Obesity; Prediabetic State; Research Design; Risk Factors

2017
Effects of the Selective Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin on Vascular Function and Central Hemodynamics in Patients With Type 2 Diabetes Mellitus.
    Circulation, 2017, 09-19, Volume: 136, Issue:12

    Topics: Administration, Oral; Adolescent; Adult; Aged; Benzhydryl Compounds; Cardiovascular Diseases; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Female; Germany; Glucosides; Hemodynamics; Humans; Male; Middle Aged; Prospective Studies; Recovery of Function; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome; Vascular Stiffness; Young Adult

2017
Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial.
    European heart journal, 2018, 02-01, Volume: 39, Issue:5

    Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome

2018
Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: A Subanalysis of EMPA-REG OUTCOME.
    Circulation, 2018, 01-23, Volume: 137, Issue:4

    Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Male; Middle Aged; Peripheral Arterial Disease; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome

2018
How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial.
    Diabetes care, 2018, Volume: 41, Issue:2

    Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dose-Response Relationship, Drug; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Placebos; Risk Factors; Treatment Outcome

2018
DECLARE-TIMI 58: Participants' baseline characteristics.
    Diabetes, obesity & metabolism, 2018, Volume: 20, Issue:5

    Topics: Aged; Benzhydryl Compounds; Body Mass Index; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Cardiomyopathies; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Glucosides; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Multicenter Studies as Topic; Obesity; Prevalence; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors

2018
Cardiovascular Mortality Reduction With Empagliflozin in Patients With Type 2 Diabetes and Cardiovascular Disease.
    Journal of the American College of Cardiology, 2018, 01-23, Volume: 71, Issue:3

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Mortality; Sodium-Glucose Transporter 2 Inhibitors

2018
Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial.
    Diabetologia, 2018, Volume: 61, Issue:8

    Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Coronary Artery Bypass; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Glomerular Filtration Rate; Glucosides; Heart Failure; Hospitalization; Humans; Hypoglycemic Agents; Kidney Diseases; Male; Middle Aged; Proportional Hazards Models; Risk; Treatment Outcome

2018
Improved cardiometabolic risk factors in Japanese patients with type 2 diabetes treated with ipragliflozin: a pooled analysis of six randomized, placebo-controlled trials.
    Endocrine journal, 2018, Jul-28, Volume: 65, Issue:7

    Topics: Aged; Blood Glucose; Body Mass Index; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Japan; Male; Middle Aged; Risk Factors; Thiophenes; Treatment Outcome

2018
Rationale and design of study of dapagliflozin versus sitagliptin treatment efficacy on prevention of cardiovascular risk factors in type 2 diabetes patients: the DIVERSITY-CVR study.
    Cardiovascular diabetology, 2018, 06-12, Volume: 17, Issue:1

    Topics: Benzhydryl Compounds; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucosides; Glycated Hemoglobin; Humans; Japan; Multicenter Studies as Topic; Prospective Studies; Randomized Controlled Trials as Topic; Risk Factors; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome

2018
Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA-REG OUTCOME
    Journal of diabetes investigation, 2019, Volume: 10, Issue:3

    Topics: Albuminuria; Asian People; Benzhydryl Compounds; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Follow-Up Studies; Glomerular Filtration Rate; Glucosides; Glycated Hemoglobin; Humans; Prognosis; Renal Insufficiency, Chronic; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors

2019
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
    The New England journal of medicine, 2019, 01-24, Volume: 380, Issue:4

    Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors

2019
Effects of DAPAgliflozin on CARDiac substrate uptake, myocardial efficiency, and myocardial contractile work in type 2 diabetes patients-a description of the DAPACARD study.
    Upsala journal of medical sciences, 2019, Volume: 124, Issue:1

    Topics: Benzhydryl Compounds; Biomarkers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Glucosides; Heart; Heart Ventricles; Hospitalization; Humans; International Cooperation; Magnetic Resonance Imaging; Metformin; Myocardial Contraction; Nuclear Medicine; Outcome Assessment, Health Care; Perfusion; Positron-Emission Tomography; Risk; Sample Size; Sodium-Glucose Transporter 2

2019
Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: A randomized controlled study.
    Clinical endocrinology, 2019, Volume: 90, Issue:6

    Topics: Adolescent; Adult; Anthropometry; Benzhydryl Compounds; Body Composition; Cardiovascular Diseases; Drug Administration Schedule; Female; Glucosides; Hormones; Humans; Life Style; Metformin; Middle Aged; Obesity; Polycystic Ovary Syndrome; Treatment Outcome; Young Adult

2019
A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF).
    European journal of heart failure, 2019, Volume: 21, Issue:5

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Chronic Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Glucosides; Heart Failure; Hospitalization; Humans; Natriuretic Peptide, Brain; Patient Reported Outcome Measures; Peptide Fragments; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume

2019
[Focus on empagliflozin : post hoc analyses of the cardiovascular outcome trial EMPA-REG OUTCOME].
    Revue medicale de Liege, 2019, Volume: 74, Issue:4

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors

2019
Analysis from the EMPA-REG OUTCOME
    Kidney international, 2019, Volume: 96, Issue:2

    Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Benzhydryl Compounds; Calcium Channel Blockers; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Diuretics; Female; Glomerular Filtration Rate; Glucosides; Humans; Kidney; Male; Middle Aged; Protective Agents; Regional Blood Flow; Renal Insufficiency, Chronic; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors

2019
Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial.
    American heart journal, 2013, Volume: 166, Issue:2

    Topics: Aged; Biomarkers; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Electrocardiography; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Research Design; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes

2013
Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension.
    Journal of the American Geriatrics Society, 2014, Volume: 62, Issue:7

    Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Humans; Male; Middle Aged; Time Factors

2014
Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™).
    Cardiovascular diabetology, 2014, Jun-19, Volume: 13

    Topics: Adult; Aged; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Prospective Studies; Research Design; Treatment Outcome; Young Adult

2014
Platelet aggregation values in patients with cardiovascular risk factors are reduced by verbascoside treatment. A randomized study.
    Pharmacological research, 2015, Volume: 97

    Topics: Adenosine Diphosphate; Aged; Capsules; Cardiovascular Diseases; Chemistry, Pharmaceutical; Double-Blind Method; Female; Glucosides; Humans; Male; Middle Aged; Phenols; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Risk Factors; Treatment Outcome

2015
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
    The New England journal of medicine, 2015, 11-26, Volume: 373, Issue:22

    Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Female; Glucosides; Hospitalization; Humans; Hypoglycemic Agents; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Middle Aged; Risk Factors

2015
[Diabetes mellitus. SGLT2 inhibitor reduces cardiovascular mortality].
    MMW Fortschritte der Medizin, 2015, Oct-08, Volume: 157, Issue:17

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Cause of Death; Combined Modality Therapy; Diabetic Angiopathies; Glucosides; Humans; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Survival Rate

2015
[Empagliflozin: an oral antidiabetic with documented positive effect on cardiac mortality].
    Praxis, 2016, Mar-16, Volume: 105, Issue:6

    Topics: Adult; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors

2016
[SGLT2 inhibition in type 2 diabetes. New study data for reducing cardiovascular risk].
    MMW Fortschritte der Medizin, 2015, Oct-22, Volume: 157, Issue:18

    Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Survival Analysis

2015
Acute effects of quercetin-3-O-glucoside on endothelial function and blood pressure: a randomized dose-response study.
    The American journal of clinical nutrition, 2016, Volume: 104, Issue:1

    Topics: Aged; Blood Pressure; Brachial Artery; Cardiovascular Diseases; Cross-Over Studies; Dose-Response Relationship, Drug; Endothelium, Vascular; Female; Flavonoids; Glucosides; Humans; Male; Middle Aged; Nitric Oxide; Plant Extracts; Quercetin; Reference Values; Vasodilation

2016
[Effect of dapagliflozin on cardiovascular risk factors].
    MMW Fortschritte der Medizin, 2016, Apr-14, Volume: 158, Issue:7

    Topics: Benzhydryl Compounds; Blood Glucose; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors

2016
SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study.
    Diabetes care, 2016, Volume: 39, Issue:5

    Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Electrolytes; Endpoint Determination; Glucosides; Glycated Hemoglobin; Hospitalization; Humans; Hypoglycemic Agents; Pioglitazone; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidinediones; Treatment Outcome

2016
[Empagliflozin also protects high risk patients].
    MMW Fortschritte der Medizin, 2016, Jun-09, Volume: 158, Issue:11

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Glucosides; Humans; Risk Factors; Survival Rate

2016
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
    The New England journal of medicine, 2016, Jul-28, Volume: 375, Issue:4

    Topics: Aged; Albuminuria; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Female; Glomerular Filtration Rate; Glucosides; Humans; Hypoglycemic Agents; Intention to Treat Analysis; Kaplan-Meier Estimate; Kidney; Male; Microvessels; Middle Aged; Proportional Hazards Models; Risk Factors

2016
Empagliflozin and Cardiovascular Outcomes in Asian Patients With Type 2 Diabetes and Established Cardiovascular Disease - Results From EMPA-REG OUTCOME
    Circulation journal : official journal of the Japanese Circulation Society, 2017, Jan-25, Volume: 81, Issue:2

    Topics: Aged; Asian People; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Myocardial Infarction; Stroke; Treatment Outcome

2017
Ingestion of quercetin inhibits platelet aggregation and essential components of the collagen-stimulated platelet activation pathway in humans.
    Journal of thrombosis and haemostasis : JTH, 2004, Volume: 2, Issue:12

    Topics: Blood Platelets; Cardiovascular Diseases; Chromatography, High Pressure Liquid; Collagen; Cross-Over Studies; Dietary Supplements; Dose-Response Relationship, Drug; Female; Flavonols; Glucosides; Humans; Immunoblotting; Male; Phosphorylation; Platelet Activation; Platelet Aggregation; Quercetin; Signal Transduction; Thrombosis; Time Factors; Tyrosine

2004
Consumption of high doses of chlorogenic acid, present in coffee, or of black tea increases plasma total homocysteine concentrations in humans.
    The American journal of clinical nutrition, 2001, Volume: 73, Issue:3

    Topics: Adult; Cardiovascular Diseases; Chlorogenic Acid; Coffee; Cross-Over Studies; Fasting; Female; Flavonoids; Folic Acid; Glucosides; Homocysteine; Humans; Male; Phenols; Polymers; Postprandial Period; Pyridoxine; Quercetin; Risk Factors; Tea; Vitamin B 12

2001

Other Studies

152 other study(ies) available for glucose, (beta-d)-isomer and Cardiovascular Diseases

ArticleYear
Role of nitric oxide in a nonseptic shock model induced by zymosan in the rat.
    Shock (Augusta, Ga.), 1997, Volume: 7, Issue:5

    Topics: Acute Disease; Animals; Ascitic Fluid; Blood Pressure; Cardiovascular Diseases; Enzyme Inhibitors; Male; Nitrates; Nitric Oxide; Nitrites; Peritonitis; Rats; Rats, Sprague-Dawley; Shock; Vasomotor System; Zymosan

1997
Effectiveness and safety of empagliflozin in routine care patients: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study.
    Diabetes, obesity & metabolism, 2022, Volume: 24, Issue:3

    Topics: Adult; Aged; Benzhydryl Compounds; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucosides; Humans; Medicare; Middle Aged; Myocardial Infarction; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; United States

2022
[Impact of dapagliflozin on cardiovascular risk factors. Beyond glycemic control].
    Semergen, 2021, Volume: 47 Suppl 1

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Glycemic Control; Heart Disease Risk Factors; Humans; Hypoglycemic Agents; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors

2021
Effect of Dapagliflozin on Hematocrit in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From DECLARE-TIMI 58.
    Diabetes care, 2022, 02-01, Volume: 45, Issue:2

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Heart Disease Risk Factors; Hematocrit; Humans; Risk Factors

2022
A Comparison of Individuals with Diabetes and EMPA-REG Trial Participants: Exploring Aspects of External Validity.
    Journal of general internal medicine, 2022, Volume: 37, Issue:11

    Topics: Adult; Benzhydryl Compounds; Cardiovascular Diseases; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Nutrition Surveys; Pregnancy; Retrospective Studies; Sodium-Glucose Transporter 2 Inhibitors

2022
Usefulness of Empagliflozin Versus Oral Semaglutide for Prevention of Cardiovascular Mortality in Patients With Type 2 Diabetes Mellitus.
    The American journal of cardiology, 2022, 05-01, Volume: 170

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucagon-Like Peptides; Glucosides; Humans; Hypoglycemic Agents; United States

2022
Cost-effectiveness of dapagliflozin compared to DPP-4 inhibitors as combination therapy with metformin in the treatment of type 2 diabetes mellitus without established cardiovascular disease in Colombia.
    Expert review of pharmacoeconomics & outcomes research, 2022, Volume: 22, Issue:6

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Colombia; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Metformin; Quality-Adjusted Life Years

2022
Empagliflozin in patients with type 2 diabetes mellitus and chronic obstructive pulmonary disease.
    Diabetes research and clinical practice, 2022, Volume: 186

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Kidney Diseases; Male; Pulmonary Disease, Chronic Obstructive; Treatment Outcome

2022
Pharmacological analysis of Empagliflozin: Acting through the CaMKII pathway in type 2 diabetes and acute cardiovascular events.
    PloS one, 2022, Volume: 17, Issue:6

    Topics: Benzhydryl Compounds; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Molecular Docking Simulation

2022
Effects of 3 months of treatment with empagliflozin on left ventricle global longitudinal strain and myocardial mechano-energetic effiency.
    Echocardiography (Mount Kisco, N.Y.), 2022, Volume: 39, Issue:8

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Heart Ventricles; Humans; Sodium-Glucose Transporter 2 Inhibitors; Ventricular Function, Left

2022
Healthberry 865
    Nutrients, 2022, Jul-16, Volume: 14, Issue:14

    Topics: Animals; Anthocyanins; Cardiovascular Diseases; Endothelial Cells; Glucosides; Humans; Oxidative Stress

2022
Cost-Effectiveness Analysis of Dapagliflozin Plus Standard Treatment for Patients With Type 2 Diabetes and High Risk of Cardiovascular Disease in China.
    Frontiers in public health, 2022, Volume: 10

    Topics: Adult; Benzhydryl Compounds; Cardiovascular Diseases; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Models, Economic

2022
Benefit of Dapagliflozin When Used With Cardiovascular Medications in Patients With Type 2 Diabetes.
    JAMA, 2022, 09-06, Volume: 328, Issue:9

    Topics: Benzhydryl Compounds; Cardiovascular Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors

2022
Architecting novel multilayer nanosponges for co-administration of two drugs managing high-risk type II diabetes mellitus patients suffering from cardiovascular diseases.
    International journal of biological macromolecules, 2022, Nov-01, Volume: 220

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Chitosan; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucosides; Humans; Hypoglycemic Agents; Linagliptin; Pharmaceutical Preparations

2022
Effect of Empagliflozin and Dapagliflozin on Ambulatory Arterial Stiffness in Patients with Type 2 Diabetes Mellitus and Cardiovascular Co-Morbidities: A Prospective, Observational Study.
    Medicina (Kaunas, Lithuania), 2022, Aug-27, Volume: 58, Issue:9

    Topics: Antihypertensive Agents; Benzhydryl Compounds; Blood Pressure Monitoring, Ambulatory; Cardiovascular Diseases; COVID-19; Diabetes Mellitus, Type 2; Glucose; Glucosides; Humans; Hypoglycemic Agents; Middle Aged; Morbidity; Pandemics; Prospective Studies; Pulse Wave Analysis; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Symporters; Treatment Outcome; Vascular Stiffness

2022
Real-world characteristics, modern antidiabetic treatment patterns, and comorbidities of patients with type 2 diabetes in central and Eastern Europe: retrospective cross-sectional and longitudinal evaluations in the CORDIALLY
    Cardiovascular diabetology, 2022, 10-08, Volume: 21, Issue:1

    Topics: Adult; Benzhydryl Compounds; Cardiovascular Diseases; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucosides; Humans; Hypoglycemic Agents; Renal Insufficiency, Chronic; Retrospective Studies; Sodium-Glucose Transporter 2 Inhibitors

2022
Comparison of cardiovascular and renal outcomes between dapagliflozin and empagliflozin in patients with type 2 diabetes without prior cardiovascular or renal disease.
    PloS one, 2022, Volume: 17, Issue:10

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucosides; Glycated Hemoglobin; Heart Failure; Humans; Hypoglycemic Agents; Lipoproteins, LDL; Renal Insufficiency, Chronic; Retrospective Studies; Sodium-Glucose Transporter 2 Inhibitors

2022
[Empagliflozin and heart failure: position paper of the experts on the results of the online meeting and discussion of the EMPEROR-Preserved Trial].
    Terapevticheskii arkhiv, 2021, Dec-15, Volume: 93, Issue:12

    Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors

2021
Budget Impact Analysis of Empagliflozin in the Treatment of Patients With Type 2 Diabetes With Established Cardiovascular Disease in South Africa.
    Value in health regional issues, 2023, Volume: 33

    Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; South Africa

2023
Cardiovascular outcomes trial data from EMPA-REG OUTCOME, CAROLINA and CARMELINA: Assessment of a novel staging system for type 2 diabetes.
    Diabetes, obesity & metabolism, 2023, Volume: 25, Issue:5

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Cardiovascular System; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Hypoglycemic Agents

2023
[In patients with moderate chronic kidney disease, including non-diabetic patients, does empagliflozin provide renal and cardiovascular benefit compared to placebo, and is it safe?]
    La Revue de medecine interne, 2023, Volume: 44, Issue:6

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Kidney; Renal Insufficiency, Chronic

2023
Diosmetin-7-O-β-D-glucopyranoside suppresses endothelial-mesenchymal transformation through endoplasmic reticulum stress in cardiac fibrosis.
    Clinical and experimental pharmacology & physiology, 2023, Volume: 50, Issue:10

    Topics: Animals; Cardiomyopathies; Cardiovascular Diseases; Collagen; Endoplasmic Reticulum Stress; Endothelial Cells; Epithelial-Mesenchymal Transition; Fibrosis; Flavonoids; Glucosides; Mice; Molecular Docking Simulation

2023
Generalizability of Cardiovascular Safety Trials on SGLT2 Inhibitors to the Real World: Implications for Clinical Practice.
    Advances in therapy, 2019, Volume: 36, Issue:10

    Topics: Aged; Aged, 80 and over; Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; United States

2019
Studies With Molecules Within the Same Class, but With Different Designs Yield Different Results. EMPA-REG, CANVAS and DECLARE.
    Revista espanola de cardiologia (English ed.), 2019, Volume: 72, Issue:12

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Clinical Trials as Topic; Global Health; Glucosides; Humans; Sodium-Glucose Transporter 2 Inhibitors; Survival Rate; Treatment Outcome

2019
Evidence from routine clinical practice: EMPRISE provides a new perspective on CVOTs.
    Cardiovascular diabetology, 2019, 08-31, Volume: 18, Issue:1

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Clinical Decision-Making; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Evidence-Based Medicine; Glucosides; Hospitalization; Humans; Practice Guidelines as Topic; Practice Patterns, Physicians'; Protective Factors; Research Design; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome

2019
Comparative risk evaluation for cardiovascular events associated with dapagliflozin vs. empagliflozin in real-world type 2 diabetes patients: a multi-institutional cohort study.
    Cardiovascular diabetology, 2019, 09-24, Volume: 18, Issue:1

    Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Databases, Factual; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Incidence; Male; Middle Aged; Retrospective Studies; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Taiwan; Time Factors; Treatment Outcome

2019
Dapagliflozin reduced cardiorenal outcomes but not MACE in T2 diabetes with or at risk for atherosclerotic CVD.
    Annals of internal medicine, 2019, 10-15, Volume: 171, Issue:8

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans

2019
SGLT2 inhibitors for primary prevention of cardiovascular events.
    Journal of diabetes, 2020, Volume: 12, Issue:1

    Topics: Benzhydryl Compounds; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Primary Prevention; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome

2020
How Many Patients with Type 2 Diabetes Meet the Inclusion Criteria of the Cardiovascular Outcome Trials with SGLT2 Inhibitors? Estimations from a Population Database in a Mediterranean Area.
    Journal of diabetes research, 2019, Volume: 2019

    Topics: Aged; Aged, 80 and over; Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Clinical Trials as Topic; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Eligibility Determination; Female; Glucosides; Glycated Hemoglobin; Humans; Male; Middle Aged; Renal Insufficiency, Chronic; Reproducibility of Results; Retrospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Spain

2019
Dapagliflozin Cut Risk of Worsening Heart Failure.
    JAMA, 2020, Jan-28, Volume: 323, Issue:4

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume

2020
Postprandial Glucose and Triglyceride Increases Along with the Endothelial Malfunction were Attenuated by the Administration of SGLT2 Inhibitor, Empagliflozin.
    Journal of atherosclerosis and thrombosis, 2020, Jul-01, Volume: 27, Issue:7

    Topics: Benzhydryl Compounds; Cardiometabolic Risk Factors; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dyslipidemias; Endothelium, Vascular; Glucose; Glucosides; Humans; Lipid Metabolism; Sodium-Glucose Transporter 2 Inhibitors; Triglycerides

2020
Sodium glucose co-transporter 2 inhibitors and cardiovascular event protections: how applicable are clinical trials and observational studies to real-world patients?
    BMJ open diabetes research & care, 2019, Volume: 7, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Blood Glucose; Bridged Bicyclo Compounds, Heterocyclic; Canagliflozin; Cardiovascular Diseases; Clinical Trials as Topic; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glucosides; Glycated Hemoglobin; Humans; Male; Middle Aged; Observational Studies as Topic; Practice Patterns, Physicians'; Retrospective Studies; Sodium-Glucose Transporter 2 Inhibitors

2019
Using the BRAVO Risk Engine to Predict Cardiovascular Outcomes in Clinical Trials With Sodium-Glucose Transporter 2 Inhibitors.
    Diabetes care, 2020, Volume: 43, Issue:7

    Topics: Adult; Benzhydryl Compounds; Blood Pressure; Canagliflozin; Cardiovascular Diseases; Cardiovascular System; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glucosides; Heart Disease Risk Factors; Humans; Hypoglycemic Agents; Male; Prognosis; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome

2020
Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: Scandinavian cohort study.
    BMJ (Clinical research ed.), 2020, 04-29, Volume: 369

    Topics: Acute Kidney Injury; Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Case-Control Studies; Cohort Studies; Comorbidity; Denmark; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucosides; Hospitalization; Humans; Kidney Diseases; Male; Middle Aged; Norway; Proportional Hazards Models; Renal Insufficiency, Chronic; Renal Replacement Therapy; Sodium-Glucose Transporter 2 Inhibitors; Sweden

2020
Budget impact analysis for dapagliflozin in type 2 diabetes in Egypt.
    Journal of medical economics, 2020, Volume: 23, Issue:8

    Topics: Benzhydryl Compounds; Budgets; Cardiovascular Diseases; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Egypt; Glucosides; Humans; Hypoglycemic Agents; Insulin; Metformin; Models, Economic; Renal Insufficiency; Sulfonylurea Compounds; Thiazolidinediones; Time Factors

2020
Empagliflozin for Patients With Presumed Resistant Hypertension: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial.
    American journal of hypertension, 2020, 12-31, Volume: 33, Issue:12

    Topics: Aged; Antihypertensive Agents; Benzhydryl Compounds; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Resistance; Drug Therapy, Combination; Female; Glucosides; Heart Failure; Hospitalization; Humans; Hypertension; Male; Middle Aged; Mortality; Sodium-Glucose Transporter 2 Inhibitors; Treatment Failure; Treatment Outcome

2020
Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Heart Failure Events in Patients with Type 2 Diabetes Mellitus: A Cost Per Outcome Analysis.
    Clinical drug investigation, 2020, Volume: 40, Issue:7

    Topics: Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Health Care Costs; Heart Failure; Humans; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors

2020
Dapagliflozin (Farxiga) - a new indication for heart failure.
    The Medical letter on drugs and therapeutics, 2020, Jun-29, Volume: 62, Issue:1601

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors

2020
Evaluating the Ability of Economic Models of Diabetes to Simulate New Cardiovascular Outcomes Trials: A Report on the Ninth Mount Hood Diabetes Challenge.
    Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2020, Volume: 23, Issue:9

    Topics: Benzhydryl Compounds; Calibration; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Models, Economic; Outcome Assessment, Health Care; Risk Assessment; Sodium-Glucose Transporter 2 Inhibitors

2020
Effect of dapagliflozin on cardiovascular events in patients with type 2 diabetes.
    Drug and therapeutics bulletin, 2021, Volume: 59, Issue:2

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans

2021
Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial.
    Circulation, 2021, 01-26, Volume: 143, Issue:4

    Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Humans; Male; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome

2021
EMPA-REG OUTCOME and beyond: the long game of cardiovascular risk reduction.
    The lancet. Diabetes & endocrinology, 2020, Volume: 8, Issue:12

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Risk Factors

2020
[In patients with moderate chronic kidney disease with albuminuria, including non-diabetic patients, does dapagliflozin provide renal and cardiovascular benefit compared to placebo?]
    La Revue de medecine interne, 2021, Volume: 42, Issue:1

    Topics: Albuminuria; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Kidney; Renal Insufficiency, Chronic

2021
SGLT2 inhibition and chronic kidney disease outcomes: in diabetes and beyond.
    The lancet. Diabetes & endocrinology, 2021, Volume: 9, Issue:1

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus; Glucosides; Humans; Kidney; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2

2021
Highlights from the European society of cardiology congress 2020.
    Journal of thrombosis and thrombolysis, 2021, Volume: 51, Issue:1

    Topics: Atrial Fibrillation; Benzhydryl Compounds; Benzylamines; Cardiomyopathy, Hypertrophic; Cardiovascular Diseases; Clinical Trials as Topic; Colchicine; Coronary Artery Disease; Europe; Glucosides; Heart Failure; Heart Valve Prosthesis; Heart Valve Prosthesis Implantation; Humans; Societies, Medical; Sodium-Glucose Transporter 2 Inhibitors; Tubulin Modulators; Uracil

2021
Empagliflozin, alone or in combination with liraglutide, limits cell death in vitro: role of oxidative stress and nitric oxide.
    Pharmacological reports : PR, 2021, Volume: 73, Issue:3

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Cell Death; Cells, Cultured; Diabetes Mellitus, Type 2; Glucagon-Like Peptide-1 Receptor; Glucosides; Humans; Hypoglycemic Agents; Liraglutide; Myocytes, Cardiac; Nitric Oxide; Nitric Oxide Synthase Type III; Oxidative Stress; Sodium-Glucose Transporter 2 Inhibitors

2021
Cost-effectiveness of Empagliflozin Compared with Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus and Established Cardiovascular Disease in Greece.
    Clinical drug investigation, 2021, Volume: 41, Issue:4

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Glucosides; Greece; Humans; Hypoglycemic Agents; Models, Economic; Quality-Adjusted Life Years

2021
Population diversity of cardiovascular outcome trials and real-world patients with diabetes in a Chinese tertiary hospital.
    Chinese medical journal, 2021, Mar-11, Volume: 134, Issue:11

    Topics: Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; China; Diabetes Mellitus, Type 2; Glucosides; Humans; Male; Sodium-Glucose Transporter 2 Inhibitors; Tertiary Care Centers

2021
Xanthone glucoside 2-β-D-glucopyranosyl-1,3,6,7-tetrahydroxy-9H-xanthen-9-one binds to the ATP-binding pocket of glycogen synthase kinase 3β and inhibits its activity: implications in prostate cancer and associated cardiovascular disease risk.
    Journal of biomolecular structure & dynamics, 2022, Volume: 40, Issue:17

    Topics: Androgen Antagonists; Androgens; Cardiovascular Diseases; Glucosides; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Male; Molecular Docking Simulation; Phosphates; Prostatic Neoplasms; Protein Isoforms; Serine; Xanthones

2022
Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease.
    BMJ open diabetes research & care, 2021, Volume: 9, Issue:1

    Topics: Adult; Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Standard of Care

2021
First-line Treatment with Empagliflozin and Metformin Combination Versus Standard Care for Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease in Qatar. A Cost-Effectiveness Analysis.
    Current problems in cardiology, 2022, Volume: 47, Issue:6

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Metformin; Qatar

2022
Cardiovascular Events, Acute Hospitalizations, and Mortality in Patients With Type 2 Diabetes Mellitus Who Initiate Empagliflozin Versus Liraglutide: A Comparative Effectiveness Study.
    Journal of the American Heart Association, 2021, Volume: 10, Issue:11

    Topics: Acute Disease; Aged; Benzhydryl Compounds; Cardiovascular Diseases; Denmark; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glucosides; Hospitalization; Humans; Hypoglycemic Agents; Liraglutide; Male; Middle Aged; Population Surveillance; Retrospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Survival Rate; Treatment Outcome

2021
Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPA-REG OUTCOME trial.
    ESC heart failure, 2021, Volume: 8, Issue:4

    Topics: Adolescent; Adult; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Male

2021
Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial.
    Diabetes care, 2021, Volume: 44, Issue:8

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glomerular Filtration Rate; Glucosides; Humans; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors

2021
Characteristics of Ventricular Electrophysiological Substrates in Metabolic Mice Treated with Empagliflozin.
    International journal of molecular sciences, 2021, Jun-05, Volume: 22, Issue:11

    Topics: Animals; Benzhydryl Compounds; Cardiovascular Diseases; Connexin 43; Connexins; Diet, High-Fat; Disease Models, Animal; Echocardiography; Electrocardiography; Gene Expression Regulation; Glucose; Glucosides; Glyburide; Humans; Metabolic Syndrome; Mice; Sodium-Glucose Transporter 2

2021
Impact of Dapagliflozin on the Left Ventricular Diastolic Function in Diabetic Patients with Heart Failure Complicating Cardiovascular Risk Factors.
    Internal medicine (Tokyo, Japan), 2021, Volume: 60, Issue:15

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diastole; Glucosides; Heart Disease Risk Factors; Heart Failure; Humans; Japan; Risk Factors; Stroke Volume; Ventricular Dysfunction, Left; Ventricular Function, Left

2021
All-Cause Mortality in Patients With Diabetes Under Treatment With Dapagliflozin: A Population-Based, Open-Cohort Study in The Health Improvement Network Database.
    The Journal of clinical endocrinology and metabolism, 2017, 05-01, Volume: 102, Issue:5

    Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Case-Control Studies; Cause of Death; Cohort Studies; Databases, Factual; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Ischemic Attack, Transient; Male; Middle Aged; Mortality; Myocardial Infarction; Myocardial Ischemia; Retrospective Studies; Stroke; Ventricular Dysfunction, Left

2017
Diabetes Drug Receives New Indication.
    The American journal of nursing, 2017, Volume: 117, Issue:4

    Topics: Acute Kidney Injury; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Drug Labeling; Drug Repositioning; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors

2017
A comparison of effects of DPP-4 inhibitor and SGLT2 inhibitor on lipid profile in patients with type 2 diabetes.
    Lipids in health and disease, 2017, Apr-13, Volume: 16, Issue:1

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Cardiomyopathies; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; Hyperglycemia; Hyperlipidemias; Linagliptin; Male; Membrane Transport Modulators; Middle Aged; Piperidones; Pyrimidines; Republic of Korea; Retrospective Studies; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors

2017
Reducing CV risk in diabetes: An ADA update.
    The Journal of family practice, 2017, Volume: 66, Issue:5

    Topics: Antihypertensive Agents; Aspirin; Benzhydryl Compounds; Cardiovascular Diseases; Contraindications; Creatinine; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Chronotherapy; Ezetimibe; Fenofibrate; Glucosides; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Hypolipidemic Agents; Life Style; Liraglutide; Metformin; Niacin; PCSK9 Inhibitors; Platelet Aggregation Inhibitors; Risk Reduction Behavior; Thiazolidinediones

2017
The reno-cardiovascular connection in the patient with Diabetes mellitus: What's new?
    Endocrinologia, diabetes y nutricion, 2017, Volume: 64, Issue:5

    Topics: Albuminuria; Anti-Inflammatory Agents; Benzhydryl Compounds; Cardiovascular Diseases; Cytokines; Diabetes Complications; Diabetic Angiopathies; Diabetic Nephropathies; Glucosides; Heart; Humans; Hypertension, Renal; Hypoglycemic Agents; Kidney; Oxidative Stress; Renin-Angiotensin System; Sodium-Glucose Transporter 2 Inhibitors; Sympathetic Nervous System

2017
EMPA-REG OUTCOME: The Nephrologist's Point of View.
    The American journal of medicine, 2017, Volume: 130, Issue:6S

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Glucosides; Humans; Hypoglycemic Agents; Kidney; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors

2017
Introduction.
    The American journal of medicine, 2017, Volume: 130, Issue:6S

    Topics: Benzhydryl Compounds; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Sodium-Glucose Transporter 2 Inhibitors

2017
EMPA-REG OUTCOME: The Cardiologist's Point of View.
    The American journal of medicine, 2017, Volume: 130, Issue:6S

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Cardiovascular Physiological Phenomena; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Glucosides; Hemodynamics; Humans; Hypoglycemic Agents; Myocardium; Oxygen Consumption; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Ventricular Function, Left

2017
EMPA-REG OUTCOME: The Endocrinologist's Point of View.
    The American journal of medicine, 2017, Volume: 130, Issue:6S

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Glucosides; Humans; Hypoglycemic Agents; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors

2017
Synergistic effects of Chuanxiong-Chishao herb-pair on promoting angiogenesis at network pharmacological and pharmacodynamic levels.
    Chinese journal of integrative medicine, 2017, Volume: 23, Issue:9

    Topics: Animals; Cardiovascular Diseases; Drug Synergism; Drugs, Chinese Herbal; Embryo, Nonmammalian; Estrogen Receptor alpha; Gene Expression Regulation; Glucosides; Ligands; Monoterpenes; Neovascularization, Physiologic; Pyrazines; Reproducibility of Results; Zebrafish

2017
Introduction.
    The American journal of cardiology, 2017, 07-01, Volume: 120, Issue:1S

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucosides; Heart Failure; Hospitalization; Humans; Myocardial Infarction; Randomized Controlled Trials as Topic; Secondary Prevention; Sodium-Glucose Transporter 2 Inhibitors; Stroke

2017
EMPA-REG OUTCOME: The Nephrologist's Point of View.
    The American journal of cardiology, 2017, 07-01, Volume: 120, Issue:1S

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Glucosides; Humans; Hypoglycemic Agents; Kidney; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors

2017
Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived?
    Diabetes care, 2017, Volume: 40, Issue:7

    Topics: Animals; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucagon-Like Peptides; Glucosides; Humans; Hyperglycemia; Hypoglycemic Agents; Liraglutide; Pioglitazone; Randomized Controlled Trials as Topic; Risk Factors; Thiazolidinediones; Treatment Outcome

2017
Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.
    The lancet. Diabetes & endocrinology, 2017, Volume: 5, Issue:8

    Topics: Aged; Albuminuria; Benzhydryl Compounds; Cardiovascular Diseases; Creatinine; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome

2017
[Cardiovascular protection of patients with type 2 diabetes : from EMPA-REG OUTCOME to LEADER].
    Revue medicale suisse, 2016, Aug-24, Volume: 12, Issue:527

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucagon-Like Peptide-1 Receptor; Glucosides; Humans; Hypoglycemic Agents; Kidney Diseases; Liraglutide; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors

2016
Can we go beyond surrogates?
    Journal of diabetes, 2017, Volume: 9, Issue:11

    Topics: Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors

2017
Letter by Tampaki et al Regarding Article, "Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk".
    Stroke, 2017, Volume: 48, Issue:9

    Topics: Benzhydryl Compounds; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Risk Factors

2017
Response by Zinman et al to Letter Regarding Article, "Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk".
    Stroke, 2017, Volume: 48, Issue:9

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Risk Factors

2017
Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study.
    Diabetes, obesity & metabolism, 2018, Volume: 20, Issue:2

    Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Denmark; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Cardiomyopathies; Dipeptidyl-Peptidase IV Inhibitors; Female; Follow-Up Studies; Glucosides; Humans; Hyperglycemia; Hypoglycemia; Incidence; Kaplan-Meier Estimate; Male; Membrane Transport Modulators; Middle Aged; Norway; Proportional Hazards Models; Risk; Sodium-Glucose Transporter 2; Sweden

2018
Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis.
    The lancet. Diabetes & endocrinology, 2017, Volume: 5, Issue:9

    Topics: Aged; Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Morbidity; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome

2017
Effect of Empagliflozin on the Metabolic Signature of Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease.
    Circulation, 2017, 09-05, Volume: 136, Issue:10

    Topics: Aged; Benzhydryl Compounds; Biomarkers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Energy Metabolism; Female; Glucosides; Humans; Male; Metabolomics; Middle Aged; Myocardium; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome

2017
Anthocyanin Cyanidin-3-Glucoside Attenuates Platelet Granule Release in Mice Fed High-Fat Diets.
    Journal of nutritional science and vitaminology, 2017, Volume: 63, Issue:4

    Topics: Animals; Anthocyanins; beta-Thromboglobulin; Blood Platelets; Cardiovascular Diseases; Chemokine CCL5; Diet; Diet, High-Fat; Dietary Supplements; Glucosides; Lipids; Male; Mice; Mice, Inbred C57BL; Platelet Activation; Platelet Factor 4; Secretory Vesicles; Serotonin; Transforming Growth Factor beta1

2017
SGLT2 inhibitors: hypotheses on the mechanism of cardiovascular protection.
    The lancet. Diabetes & endocrinology, 2018, Volume: 6, Issue:6

    Topics: Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Complications; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome

2018
Cost-utility of empagliflozin in patients with type 2 diabetes at high cardiovascular risk.
    Journal of diabetes and its complications, 2018, Volume: 32, Issue:2

    Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Costs; Female; Glucosides; Humans; Male; Middle Aged; Morbidity; Quality-Adjusted Life Years; Risk Factors; Treatment Outcome

2018
Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias?
    Diabetes care, 2018, Volume: 41, Issue:1

    Topics: Benzhydryl Compounds; Bias; Canagliflozin; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Follow-Up Studies; Glucosides; Humans; Hypoglycemic Agents; Insulin; Mortality; Observational Studies as Topic; Randomized Controlled Trials as Topic; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors

2018
Sodium/Glucose Cotransporter 2 Inhibitors in Patients With Diabetes Mellitus and Chronic Kidney Disease: Turning the Page.
    Circulation, 2018, 01-09, Volume: 137, Issue:2

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucose; Glucosides; Humans; Renal Insufficiency, Chronic; Sodium

2018
Cost-Effectiveness of Empagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus at Increased Cardiovascular Risk in Greece.
    Clinical drug investigation, 2018, Volume: 38, Issue:5

    Topics: Adult; Benzhydryl Compounds; Cardiovascular Diseases; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Glucosides; Greece; Humans; Hypoglycemic Agents; Middle Aged; Models, Economic; Quality-Adjusted Life Years; Risk Factors; Treatment Outcome

2018
[SGLT2 inhibitor or GLP-1 receptor agonist in a patient with type 2 diabetes and cardiovascular disease ?]
    Revue medicale de Liege, 2018, Volume: 73, Issue:1

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucagon-Like Peptide-1 Receptor; Glucosides; Humans; Hypoglycemic Agents; Liraglutide; Sodium-Glucose Transporter 2 Inhibitors

2018
Eligibility varies among the 4 sodium-glucose cotransporter-2 inhibitor cardiovascular outcomes trials: implications for the general type 2 diabetes US population.
    The American journal of managed care, 2018, Volume: 24, Issue:8 Suppl

    Topics: Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors

2018
Are the favorable cardiovascular outcomes of empagliflozin treatment explained by its effects on multiple cardiometabolic risk factors? A simulation of the results of the EMPA-REG OUTCOME trial.
    Diabetes research and clinical practice, 2018, Volume: 141

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Risk Factors; Treatment Outcome

2018
Use of GLP-1 RAs in Cardiovascular Disease Prevention: A Practical Guide.
    Circulation, 2018, 05-22, Volume: 137, Issue:21

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucagon-Like Peptide-1 Receptor; Glucosides; Humans; Hypoglycemic Agents; Liraglutide

2018
In type 2 diabetes with CVD and kidney disease, empagliflozin reduced mortality and hospitalization.
    Annals of internal medicine, 2018, 05-15, Volume: 168, Issue:10

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Hospitalization; Humans; Renal Insufficiency, Chronic

2018
Usefulness of Empagliflozin Versus Liraglutide for Prevention of Cardiovascular Mortality.
    The American journal of cardiology, 2018, 09-15, Volume: 122, Issue:6

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Costs; Female; Glucosides; Humans; Hypoglycemic Agents; Liraglutide; Male; Middle Aged; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors

2018
Antihyperglycemic medications for cardiovascular disease risk reduction.
    The American journal of managed care, 2018, Volume: 24, Issue:13 Suppl

    Topics: Benzhydryl Compounds; Bromocriptine; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Glucosides; Humans; Hypoglycemic Agents; Risk Reduction Behavior; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidinediones

2018
Long-Term Benefit of Empagliflozin on Life Expectancy in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease.
    Circulation, 2018, 10-09, Volume: 138, Issue:15

    Topics: Aged; Aged, 80 and over; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus; Female; Glucosides; Humans; Life Expectancy; Male; Middle Aged; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Survival Analysis; Time Factors; Treatment Outcome

2018
Improvement in Cardiovascular Outcomes With Empagliflozin Is Independent of Glycemic Control.
    Circulation, 2018, 10-23, Volume: 138, Issue:17

    Topics: Benzhydryl Compounds; Biomarkers; Blood Glucose; Cardiovascular Diseases; Clinical Decision-Making; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Randomized Controlled Trials as Topic; Recovery of Function; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome

2018
Letter by Koh Regarding Article, "Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease".
    Circulation, 2018, 08-21, Volume: 138, Issue:8

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Renal Insufficiency, Chronic

2018
Response by Wanner et al to Letters Regarding Article, "Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease".
    Circulation, 2018, 08-21, Volume: 138, Issue:8

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Renal Insufficiency, Chronic

2018
Letter by Tampakis et al Regarding Article, "Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease".
    Circulation, 2018, 08-21, Volume: 138, Issue:8

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Renal Insufficiency, Chronic

2018
Economic modelling of costs associated with outcomes reported for type 2 diabetes mellitus (T2DM) patients in the CANVAS and EMPA-REG cardiovascular outcomes trials.
    Journal of medical economics, 2019, Volume: 22, Issue:3

    Topics: Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Health Expenditures; Humans; Hypoglycemic Agents; Models, Economic; Sodium-Glucose Transporter 2 Inhibitors

2019
Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLARE-TIMI 58 trial: A nationwide observational study.
    Diabetes, obesity & metabolism, 2019, Volume: 21, Issue:5

    Topics: Adult; Aged; Benzhydryl Compounds; Cardiovascular Diseases; Clinical Trials as Topic; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glucosides; Humans; Male; Middle Aged; Research Design; Sweden; Treatment Outcome

2019
    International journal of STEM education, 2017, Volume: 4, Issue:1

    Topics: Adult; Aged; Animals; Antigens, Helminth; Apoptosis; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Carcinogenesis; Cardiovascular Diseases; Cell Line; Cell Nucleus; Cell Proliferation; Databases, Factual; Diabetes Complications; Diabetes Mellitus, Type 2; Endosonography; Feces; Female; Glomerular Filtration Rate; Glucosides; Glutathione; Humans; Logistic Models; Male; Middle Aged; Ovum; Oxidative Stress; Pancreas; Pancreatic Elastase; Pancreatitis, Chronic; Patient Safety; Predictive Value of Tests; Prevalence; Proportional Hazards Models; Prospective Studies; Prostate; Risk Factors; Schistosoma; Schistosomiasis; Scotland; Severity of Illness Index; Sodium-Glucose Transporter 2 Inhibitors; Systole; Treatment Outcome

2017
An evaluation of the efficacy and safety of Tofogliflozin for the treatment of type II diabetes.
    Expert opinion on pharmacotherapy, 2019, Volume: 20, Issue:7

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Half-Life; Humans; Hypoglycemia; Ketosis; Kidney Diseases; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome

2019
Dapagliflozin and cardiovascular outcomes: anything else to DECLARE?
    Expert opinion on pharmacotherapy, 2019, Volume: 20, Issue:9

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Glucosides; Humans; Sodium-Glucose Transporter 2 Inhibitors

2019
Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart Failure.
    Circulation. Heart failure, 2019, Volume: 12, Issue:6

    Topics: Adult; Aged; Albuminuria; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Rate; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Kidney; Male; Middle Aged; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors

2019
Hyperlipidaemia and cardiovascular disease -- newer antihyperglycaemic agents and cardiovascular disease.
    Current opinion in lipidology, 2013, Volume: 24, Issue:2

    Topics: Benzhydryl Compounds; Blood Pressure; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Glucosides; Humans; Hyperlipidemias; Hypoglycemic Agents; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome

2013
Activation of mitochondrial function and Hb expression in non-haematopoietic cells by an EPO inducer ameliorates ischaemic diseases in mice.
    British journal of pharmacology, 2013, Volume: 169, Issue:7

    Topics: Animals; Cardiovascular Diseases; Cell Line; Cells, Cultured; Cisplatin; Doxorubicin; Erythropoietin; Glucosides; HEK293 Cells; Hemoglobins; Hepatocytes; Humans; Kidney; Male; Mice; Mice, Inbred C57BL; Mitochondria; Myocytes, Cardiac; Receptors, Erythropoietin; Stilbenes

2013
Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes.
    Diabetes, obesity & metabolism, 2014, Volume: 16, Issue:7

    Topics: Amputation, Surgical; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Retinopathy; Disease Progression; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incidence; Kidney Failure, Chronic; Metformin; Microcirculation; Middle Aged; Myocardial Infarction; Nutrition Surveys; Sodium-Glucose Transporter 2 Inhibitors; Stroke; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Uric Acid

2014
Refitting of the UKPDS 68 risk equations to contemporary routine clinical practice data in the UK.
    PharmacoEconomics, 2015, Volume: 33, Issue:2

    Topics: Adult; Aged; Benzhydryl Compounds; Cardiovascular Diseases; Cost-Benefit Analysis; Databases, Factual; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Incidence; Male; Metformin; Middle Aged; Models, Economic; Risk Factors; Sulfonylurea Compounds; United Kingdom

2015
Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice.
    Cardiovascular diabetology, 2014, Oct-26, Volume: 13

    Topics: Animals; Benzhydryl Compounds; Blood Glucose; Cardiovascular Diseases; Cognition Disorders; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucosides; Hypoglycemic Agents; Male; Mice, Inbred C57BL; Obesity; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors

2014
The cardiovascular effects of salidroside in the Goto-Kakizaki diabetic rat model.
    Journal of physiology and pharmacology : an official journal of the Polish Physiological Society, 2015, Volume: 66, Issue:2

    Topics: Animals; Aorta; Blood Pressure; Cardiotonic Agents; Cardiovascular Diseases; Cardiovascular System; Diabetes Mellitus, Type 2; Endothelium, Vascular; Glucose Intolerance; Glucosides; Guanylate Cyclase; Heart Rate; Hyperglycemia; Hypertension; Male; Myocytes, Smooth Muscle; Nitric Oxide Synthase Type III; Phenols; Rats; Rats, Inbred WKY; Receptors, Cytoplasmic and Nuclear; Soluble Guanylyl Cyclase; Vasodilation

2015
Understanding EMPA-REG OUTCOME.
    The lancet. Diabetes & endocrinology, 2015, Volume: 3, Issue:12

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male

2015
Understanding EMPA-REG OUTCOME.
    The lancet. Diabetes & endocrinology, 2015, Volume: 3, Issue:12

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male

2015
Understanding EMPA-REG OUTCOME.
    The lancet. Diabetes & endocrinology, 2015, Volume: 3, Issue:12

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male

2015
Preventing cardiovascular events with empagliflozin: at what cost?
    The lancet. Diabetes & endocrinology, 2015, Volume: 3, Issue:12

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male

2015
Cardiovascular Risk and Sodium-Glucose Cotransporter 2 Inhibition in Type 2 Diabetes.
    The New England journal of medicine, 2015, Nov-26, Volume: 373, Issue:22

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male

2015
Superiority trials: statistical trickery or mass blindness?
    Postgraduate medical journal, 2016, Volume: 92, Issue:1084

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male

2016
[EMPA-REG OUTCOME: Empagliflozin reduces mortality in patients with type 2 diabetes at high cardiovascular risk].
    Revue medicale de Liege, 2015, Volume: 70, Issue:11

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Hospitalization; Humans; Hypoglycemic Agents; Randomized Controlled Trials as Topic

2015
ACP Journal Club. In patients with type 2 diabetes and CV disease, empagliflozin reduced a composite of CV events at 3.1 years.
    Annals of internal medicine, 2016, Jan-19, Volume: 164, Issue:2

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male

2016
Reduction in cardiovascular and all-cause mortality in the EMPA-REG OUTCOME trial: A critical analysis.
    Diabetes & metabolism, 2016, Volume: 42, Issue:2

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents

2016
Editorial: The New Trial EMPAREG-OUTCOMES in Type 2 Diabetes: "and Death Shall Have no Dominion"?
    Current vascular pharmacology, 2016, Volume: 14, Issue:4

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents

2016
[Empagliflozin reduces heart failure risk by a third].
    MMW Fortschritte der Medizin, 2015, Dec-14, Volume: 157, Issue:21-22

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Glucosides; Heart Failure; Humans; Outcome Assessment, Health Care; Risk; Survival Rate

2015
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
    The New England journal of medicine, 2016, 03-17, Volume: 374, Issue:11

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male

2016
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
    The New England journal of medicine, 2016, 03-17, Volume: 374, Issue:11

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male

2016
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
    The New England journal of medicine, 2016, 03-17, Volume: 374, Issue:11

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male

2016
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
    The New England journal of medicine, 2016, 03-17, Volume: 374, Issue:11

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male

2016
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
    The New England journal of medicine, 2016, 03-17, Volume: 374, Issue:11

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male

2016
[Comment by Prof. Dr. med Dirk Müller-Wieland. The therapeutic goal for blood sugar lowering in diabetes treatment].
    Medizinische Monatsschrift fur Pharmazeuten, 2016, Volume: 39, Issue:2

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male

2016
Glycemic control and the heart: it matters how you get there.
    Journal of diabetes, 2016, Volume: 8, Issue:4

    Topics: Benzhydryl Compounds; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus; Glucosides; Humans; Hypoglycemic Agents; Liraglutide; Outcome Assessment, Health Care; Pioglitazone; Thiazolidinediones

2016
Long-term maintenance of efficacy of dapagliflozin in patients with type 2 diabetes mellitus and cardiovascular disease.
    Diabetes, obesity & metabolism, 2016, Volume: 18, Issue:8

    Topics: Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Hypovolemia; Longitudinal Studies; Maintenance Chemotherapy; Male; Middle Aged; Renal Insufficiency; Urinary Tract Infections

2016
Increased grip strength with sodium-glucose cotransporter 2.
    Journal of diabetes, 2016, Volume: 8, Issue:5

    Topics: Aged; Benzhydryl Compounds; Body Mass Index; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Hand Strength; Humans; Hypoglycemic Agents; Male; Middle Aged; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome

2016
Clinical Implications of Cardiovascular Outcome Trials in Type 2 Diabetes: From DCCT to EMPA-REG.
    Clinical therapeutics, 2016, Volume: 38, Issue:6

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Glucosides; Humans; Hypoglycemic Agents; Insulin; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors

2016
[The cardiovascular outcome is critical].
    MMW Fortschritte der Medizin, 2016, Feb-18, Volume: 158, Issue:3

    Topics: Benzhydryl Compounds; Biosimilar Pharmaceuticals; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Insulin Glargine

2016
EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Clinical therapeutics, 2016, Volume: 38, Issue:6

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon-Like Peptide-1 Receptor; Glucosides; Humans; Hypoglycemic Agents; Metformin; Pioglitazone; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidinediones

2016
Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis.
    Diabetes care, 2016, Volume: 39, Issue:7

    Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Energy Metabolism; Glucosides; Heart; Humans; Hypoglycemic Agents; Kidney; Models, Biological; Research Design; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome

2016
CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
    Diabetes care, 2016, Volume: 39, Issue:7

    Topics: 3-Hydroxybutyric Acid; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Glucosides; Heart; Humans; Hypoglycemic Agents; Models, Biological; Research Design; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome

2016
Cardiac and Renovascular Complications in Type 2 Diabetes--Is There Hope?
    The New England journal of medicine, 2016, Jul-28, Volume: 375, Issue:4

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glucosides; Humans; Hypoglycemic Agents; Liraglutide; Male

2016
Long-Term Safety of Dapagliflozin in Older Patients with Type 2 Diabetes Mellitus: A Pooled Analysis of Phase IIb/III Studies.
    Drugs & aging, 2016, Volume: 33, Issue:7

    Topics: Adult; Aged; Benzhydryl Compounds; Cardiovascular Diseases; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Female; Fractures, Bone; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Kidney; Male; Middle Aged; Risk Factors; Safety; Urinary Tract Infections

2016
SGLT2 Inhibitors and the Diabetic Kidney.
    Diabetes care, 2016, Volume: 39 Suppl 2

    Topics: Albuminuria; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glomerular Filtration Rate; Glucosides; Humans; Hypoglycemic Agents; Kidney; Kidney Failure, Chronic; Kidney Glomerulus; Renin-Angiotensin System; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors

2016
London buses: A cardiovascular outcome trial equivalent?
    Diabetes & vascular disease research, 2016, Volume: 13, Issue:6

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Incretins; Liraglutide; Protective Factors; Risk Factors; Treatment Outcome

2016
New Treatments for Type 2 Diabetes Mellitus and Cardiovascular Disease. The Revolution Has Begun.
    Revista espanola de cardiologia (English ed.), 2016, Volume: 69, Issue:11

    Topics: Adamantane; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide-1 Receptor; Glucosides; Humans; Hypoglycemic Agents; Liraglutide; Peptides; Piperidines; Risk; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Uracil

2016
Renoprotection in LEADER and EMPA-REG OUTCOME.
    The lancet. Diabetes & endocrinology, 2016, Volume: 4, Issue:10

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2

2016
Diabetes medications improve cardiovascular outcomes: the paradigm shifts.
    Current opinion in lipidology, 2016, Volume: 27, Issue:6

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Liraglutide

2016
A new era in the management of type 2 diabetes: Is cardioprotection at long last a reality?
    International journal of cardiology, 2017, Feb-01, Volume: 228

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Liraglutide

2017
Obesity Week 2016 Annual Meeting.
    Journal of diabetes, 2017, Volume: 9, Issue:3

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Congresses as Topic; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Liraglutide; Prediabetic State; Quality of Life; Treatment Outcome; Weight Loss

2017
Impact of empagliflozin on diabetic kidney disease.
    Journal of diabetes investigation, 2017, Volume: 8, Issue:5

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetic Nephropathies; Glucosides; Humans; Hypoglycemic Agents; Randomized Controlled Trials as Topic; Treatment Outcome

2017
Reverse causality in Empa-Reg Outcome: The proverbial elephant?
    Diabetes research and clinical practice, 2017, Volume: 127

    Topics: Animals; Benzhydryl Compounds; Cardiovascular Diseases; Causality; Diabetes Mellitus, Type 2; Elephants; Glucosides; Humans; Hypoglycemic Agents; Reverse Transcriptase Polymerase Chain Reaction; Sodium-Glucose Transporter 2; Treatment Outcome

2017
The cardiovascular benefits of empagliflozin: SGLT2-dependent and -independent effects.
    Diabetologia, 2017, Volume: 60, Issue:3

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Cardiomyopathies; Glucosides; Humans; Hypoglycemic Agents; Membrane Transport Modulators; Models, Biological; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors

2017
Asian Perspective of the EMPA-REG OUTCOME Study.
    Circulation journal : official journal of the Japanese Circulation Society, 2017, Jan-25, Volume: 81, Issue:2

    Topics: Asian People; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Outcome Assessment, Health Care

2017
Novel oral glucose-lowering drugs are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes.
    Diabetes, obesity & metabolism, 2017, Volume: 19, Issue:6

    Topics: Administration, Oral; Aged; Benzhydryl Compounds; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Propensity Score; Proportional Hazards Models; Registries; Risk Factors; Sweden

2017
[Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk factors and the cardiovascular system].
    Giornale italiano di cardiologia (2006), 2016, Volume: 17, Issue:12 Suppl 2

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Cardiovascular System; Glucagon-Like Peptide-1 Receptor; Glucosides; Humans; Hypoglycemic Agents; Liraglutide; Risk Factors

2016
SGLT2 inhibitor empagliflozin reduces renal outcomes and dampens the progressive reduction in glomerular filtration rate in patients with type 2 diabetes and antecedents of cardiovascular disease.
    Evidence-based medicine, 2017, Volume: 22, Issue:2

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glomerular Filtration Rate; Glucosides; Humans

2017
Empa's New Clothes: The Untold Story of the Empa-Reg Outcome Trial.
    Diabetes technology & therapeutics, 2017, Volume: 19, Issue:6

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Controlled Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Cardiomyopathies; Drug Approval; Glucosides; Humans; Hyperglycemia; Hypoglycemic Agents; Mortality; Multicenter Studies as Topic; Survival Analysis

2017
Plant food delphinidin-3-glucoside significantly inhibits platelet activation and thrombosis: novel protective roles against cardiovascular diseases.
    PloS one, 2012, Volume: 7, Issue:5

    Topics: AMP-Activated Protein Kinases; Analysis of Variance; Animals; Anthocyanins; Bleeding Time; Cardiovascular Diseases; CD40 Ligand; Flow Cytometry; Gene Expression Regulation; Glucosides; Humans; In Vitro Techniques; Mice; Mice, Inbred C57BL; P-Selectin; Phosphorylation; Platelet Activation; Tetraspanin 30; Thrombosis

2012
[Treatment of cardiac patients with cardipyrine Hommel].
    Praxis, 1950, Jun-01, Volume: 39, Issue:22

    Topics: Cardiovascular Diseases; Digitalis; Digitalis Glycosides; Glucosides; Humans; Plant Extracts

1950
[Effect of olitoriside and vitamin B12 on the content of adenylic nucleotides in the myocardium in acute cardiovascular insufficiency].
    Vrachebnoe delo, 1981, Issue:8

    Topics: Adenine Nucleotides; Animals; Cardenolides; Cardiac Glycosides; Cardiovascular Diseases; Drug Therapy, Combination; Female; Glucosides; Glycosides; Male; Myocardium; Rats; Vitamin B 12

1981
chemdatabank.com